# Immune checkpoint inhibitors: recent progress and pot

Experimental and Molecular Medicine

50, 1-11

DOI: 10.1038/s12276-018-0191-1

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity, 2019, 52, 144-160. | 1.2 | 10 |
| 2 | Are mimotope vaccines a good alternative to monoclonal antibodies?. Immunotherapy, 2019, 11, 795-800. | 1.0 | 9 |
| 3 | Chronic Implant-Related Bone Infectionsâ€"Can Immune Modulation be a Therapeutic Strategy?. Frontiers in Immunology, 2019, 10, 1724. | 2.2 | 124 |
| 4 | The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. International Journal of Molecular Sciences, 2019, 20, 3899. | 1.8 | 21 |
| 5 | Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Medicine, 2019, 8, 5399-5413. | 1.3 | 15 |
| 6 | Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3KÎ² Inhibition in PTEN Loss Melanoma. Clinical Cancer Research, 2019, 25, 6406-6416. | 3.2 | 35 |
| 7 | Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy. Immunotherapy, 2019, 11, 1117-1128. | 1.0 | 15 |
| 8 | Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 2019, 11, 971. | 1.7 | 87 |
| 9 | Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189. | | 41 |
| 10 | Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. Medical Oncology, 2019, 36, 72. | 1.2 | 4 |
| 11 | Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. Frontiers in Immunology, 2019, 10, 1690. | 2.2 | 71 |
| 12 | Î²2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment, 2019, 177, 603-610. | 1.1 | 22 |
| 13 | Hypoxia-inducible factor-2Î± and refractory nsclc: Further evidence to support the use of immune-checkpoint inhibitors?. Pulmonary Pharmacology and Therapeutics, 2019, 57, 101815. | 1.1 | 0 |
| 14 | Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model. Translational Oncology, 2019, 12, 1264-1270. | 1.7 | 2 |
| 15 | A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250. | 15.2 | 133 |
| 16 | The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients. International Immunopharmacology, 2019, 74, 105745. | 1.7 | 49 |
| 17 | Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates, 2019, 45, 13-29. | 6.5 | 82 |
| 18 | Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications, 2019, 10, 4712. | 5.8 | 76 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning. Cancers, 2019, 11, 1562. | 1.7 | 31 |
| 20 | Immunomodulatory receptors are differentially expressed in B and T cell subsets relevant to autoimmune disease. Clinical Immunology, 2019, 209, 108276. | 1.4 | 17 |
| 21 | Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. International Immunopharmacology, 2019, 77, 105957. | 1.7 | 32 |
| 22 | Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9, 7906-7923. | 4.6 | 100 |
| 23 | Immunotherapy and other systemic therapies for cutaneous SCC. Oral Oncology, 2019, 99, 104459. | 0.8 | 17 |
| 24 | The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. Frontiers in Immunology, 2019, 10, 2354. | 2.2 | 70 |
| 25 | B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells. Journal of Clinical Medicine, 2019, 8, 1928. | 1.0 | 13 |
| 26 | Role of a novel circulatory RNAâ€based biomarker panel expression in ovarian cancer. IUBMB Life, 2019, 71, 2031-2047. | 1.5 | 5 |
| 27 | Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 568-586. | 12.8 | 557 |
| 28 | MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function. International Journal of Molecular Sciences, 2019, 20, 4287. | 1.8 | 28 |
| 29 | Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy. Vaccines, 2019, 7, 109. | 2.1 | 10 |
| 30 | The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986976. | 1.4 | 31 |
| 31 | Anal cancer and immunotherapyâ€"are we there yet?. Translational Gastroenterology and Hepatology, 2019, 4, 57-57. | 1.5 | 8 |
| 32 | Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. European Journal of Medicinal Chemistry, 2019, 183, 111741. | 2.6 | 10 |
| 33 | Employing Parasite Against Cancer: A Lesson From the Canine Tapeworm Echinococcus Granulocus. Frontiers in Pharmacology, 2019, 10, 1137. | 1.6 | 18 |
| 34 | Current concepts of non-coding RNA regulation of immune checkpoints in cancer. Molecular Aspects of Medicine, 2019, 70, 117-126. | 2.7 | 41 |
| 35 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. Genes, 2019, 10, 709. | 1.0 | 71 |
| 36 | Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056. | 15.2 | 773 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The Evolving Role of CD8+CD28â˜ Immunosenescent T Cells in Cancer Immunology. International Journal of Molecular Sciences, 2019, 20, 2810. | 1.8 | 105 |
| 38 | Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255. | 3.5 | 577 |
| 39 | Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. Cells, 2019, 8, 470. | 1.8 | 143 |
| 40 | Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negativeÂoperated breast cancers. Breast Cancer, 2019, 26, 738-747. | 1.3 | 21 |
| 41 | The Novel Aspects on the Mosaic of Autoimmunity. , 2019, , 7-11. | | 2 |
| 42 | The bodyâ€™s civil war: Understanding autoimmune conditions. Independent Nurse, 2019, 2019, 27-30. | 0.0 | 0 |
| 43 | Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529. | 1.0 | 17 |
| 44 | Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2019, 380, 1597-1605. | 13.9 | 260 |
| 45 | Chondroitin Sulfate-Based pH-Sensitive Polymer-Modified Liposomes for Intracellular Antigen Delivery and Induction of Cancer Immunity. Bioconjugate Chemistry, 2019, 30, 1518-1529. | 1.8 | 28 |
| 46 | Targeting Tumor Microenvironment for Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 840. | 1.8 | 822 |
| 47 | Chlorin e6-Conjugated and PEGylated Immune Checkpoint Inhibitor Nanocomposites for Pulmonary Metastatic Colorectal Cancer. ACS Omega, 2019, 4, 18593-18599. | 1.6 | 7 |
| 48 | Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers, 2019, 11, 1822. | 1.7 | 106 |
| 49 | Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports, 2019, 9, 16662. | 1.6 | 33 |
| 50 | Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. Frontiers in Immunology, 2019, 10, 2936. | 2.2 | 97 |
| 51 | The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Frontiers in Oncology, 2019, 9, 1366. | 1.3 | 50 |
| 52 | Unmasking the Many Faces of Tumor-Associated Neutrophils and Macrophages: Considerations for Targeting Innate Immune Cells in Cancer. Trends in Cancer, 2019, 5, 789-798. | 3.8 | 56 |
| 53 | Molecular Imaging in Pediatric Brain Tumors. Cancers, 2019, 11, 1853. | 1.7 | 12 |
| 54 | Red biotechnology: A healthy world. AIP Conference Proceedings, 2019, , . | 0.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development. Cancers, 2019, 11, 1989. | 1.7 | 18 |
| 56 | Integrated genomic profiling expands clinical options for patients with cancer. Nature Biotechnology, 2019, 37, 1351-1360. | 9.4 | 103 |
| 57 | Single-cell immune landscape of human atherosclerotic plaques. Nature Medicine, 2019, 25, 1576-1588. | 15.2 | 540 |
| 58 | Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers, 2019, 11, 1972. | 1.7 | 8 |
| 59 | Immune checkpoints in the tumor microenvironment. Seminars in Cancer Biology, 2020, 65, 1-12. | 4.3 | 146 |
| 60 | Near-Infrared Photoimmunotherapy: Photoactivatable Antibodyâ€“Drug Conjugates (ADCs). Bioconjugate Chemistry, 2020, 31, 28-36. | 1.8 | 45 |
| 61 | Clinical and Morphological Characteristics of Antiâ€“Programmed Death Ligand 1â€“Associated Retinopathy. Ophthalmology Retina, 2020, 4, 446-450. | 1.2 | 15 |
| 62 | Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2020, 8, 108-119. | 1.6 | 187 |
| 63 | TIGIT as an emerging immune checkpoint. Clinical and Experimental Immunology, 2020, 200, 108-119. | 1.1 | 310 |
| 64 | Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respiratory Medicine, 2020, 161, 105853. | 1.3 | 23 |
| 65 | Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. Oral Oncology, 2020, 100, 104477. | 0.8 | 9 |
| 66 | Toward a Better Understanding of Hepatocellular Carcinoma Immune Infiltrates. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 341-342. | 2.3 | 2 |
| 67 | Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma. Frontiers in Immunology, 2020, 11, 2105. | 2.2 | 164 |
| 68 | Flow Cytometric Analyses of Lymphocyte Markers in Immune Oncology: A Comprehensive Guidance for Validation Practice According to Laws and Standards. Frontiers in Immunology, 2020, 11, 2169. | 2.2 | 14 |
| 69 | The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life, 2020, 10, 219. | 1.1 | 11 |
| 70 | Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 587460. | 2.2 | 87 |
| 71 | Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 755-769. | 1.0 | 9 |
| 72 | Self-Assembly as a Molecular Strategy to Improve Immunotherapy. Accounts of Chemical Research, 2020, 53, 2534-2545. | 7.6 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Atezolizumab-Induced Bellâ€™s Palsy in a Patient With Small Cell Lung Cancer. Journal of Investigative Medicine High Impact Case Reports, 2020, 8, 232470962096501. | 0.3 | 3 |
| 74 | TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. Journal of Biopharmaceutical Statistics, 2020, 30, 979-992. | 0.4 | 11 |
| 75 | Cordyceps militaris Induces Immunogenic Cell Death and Enhances Antitumor Immunogenic Response in Breast Cancer. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11. | 0.5 | 6 |
| 76 | Predicting the Efficacy and Safety of TACTICs (Tumor Angiogenesis-Specific CAR-T Cells Impacting) Tj ETQq1 1 0.784314 rgBT /Overlo | 1.7 | 6 |
| 77 | Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. Journal of Autoimmunity, 2020, 115, 102546. | 3.0 | 13 |
| 78 | Immune Checkpoint Inhibitor Therapy Aggravates T Cellâ€“Driven Plaque Inflammation in Atherosclerosis. JACC: CardioOncology, 2020, 2, 599-610. | 1.7 | 69 |
| 79 | Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer. Pathology Research and Practice, 2020, 216, 153188. | 1.0 | 5 |
| 80 | In-depth characterization of the biomarkers based on tumor-infiltrated immune cells reveals implications for diagnosis and prognosis in hepatocellular carcinoma. Journal of Translational Autoimmunity, 2020, 3, 100067. | 2.0 | 6 |
| 81 | Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 3337-3345. | 0.8 | 12 |
| 82 | Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. International Journal of Molecular Sciences, 2020, 21, 7621. | 1.8 | 12 |
| 83 | Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences, 2020, 21, 7743. | 1.8 | 36 |
| 84 | The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 7358. | 1.8 | 48 |
| 85 | Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Human Molecular Genetics, 2020, 29, R214-R225. | 1.4 | 3 |
| 86 | Main Strategies for the Identification of Neoantigens. Cancers, 2020, 12, 2879. | 1.7 | 32 |
| 87 | Tumor resistance mechanisms and their consequences on Î³Î´ T cell activation. Immunological Reviews, 2020, 298, 84-98. | 2.8 | 33 |
| 88 | Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for nonâ€“small cell lung cancer and melanoma brain metastases. Cancer, 2020, 126, 5274-5282. | 2.0 | 19 |
| 89 | Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncology, 2020, 109, 104977. | 0.8 | 10 |
| 90 | Clinical outcomes of coronavirus disease 2019 (COVIDâ€19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Communications, 2020, 40, 374-379. | 3.7 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. Journal of Controlled Release, 2020, 326, 203-221. | 4.8 | 33 |
| 92 | A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapyâ€"Related Toxicity: A Primer for the Radiologist. American Journal of Roentgenology, 2020, 215, 770-780. | 1.0 | 4 |
| 93 | Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. Pharmaceutics, 2020, 12, 663. | 2.0 | 24 |
| 94 | PK/PD-driven starting and effective human dose determination for immuno-oncology drugs. , 2020, , 657-667. | | 0 |
| 95 | Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€BAM, TLR Ligands, and Antiâ€CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044. | 1.6 | 11 |
| 96 | QSPâ€IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immunoâ€Oncology Applications. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 484-497. | 1.3 | 34 |
| 97 | Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 8627. | 1.8 | 51 |
| 98 | Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection. Cancers, 2020, 12, 3383. | 1.7 | 11 |
| 99 | The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?. International Journal of Molecular Sciences, 2020, 21, 8678. | 1.8 | 32 |
| 100 | Fc-Engineering for Modulated Effector Functionsâ€"Improving Antibodies for Cancer Treatment. Antibodies, 2020, 9, 64. | 1.2 | 93 |
| 101 | Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. , 2020, 8, e001392. | | 27 |
| 102 | Ecological and Evolutionary Consequences of Anticancer Adaptations. IScience, 2020, 23, 101716. | 1.9 | 10 |
| 103 | A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer. Frontiers in Pharmacology, 2020, 11, 585255. | 1.6 | 21 |
| 104 | Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy. Seminars in Immunology, 2020, 49, 101434. | 2.7 | 7 |
| 105 | SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 3521. | 1.7 | 7 |
| 106 | Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058. | 1.3 | 5 |
| 107 | Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers, 2020, 12, 3301. | 1.7 | 22 |
| 108 | Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. Cancers, 2020, 12, 3550. | 1.7 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 9023. | 1.8 | 16 |
| 110 | Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response. Cancers, 2020, 12, 3600. | 1.7 | 9 |
| 111 | SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705. | | 20 |
| 112 | Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. Journal of Immunology Research, 2020, 2020, 1-9. | 0.9 | 2 |
| 113 | Epigenetic regulation of immune checkpoints and TÂcell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics, 2020, 12, 1871-1882. | 1.0 | 11 |
| 114 | Inhibitory Receptor Trap: A Platform for Discovery of Inhibitory Receptors That Utilize Inositol Lipid and Phosphotyrosine Phosphatase Effectors. Frontiers in Immunology, 2020, 11, 592329. | 2.2 | 5 |
| 115 | Past, Present, and Future of Anticancer Nanomedicine . International Journal of Nanomedicine, 2020, Volume 15, 5719-5743. | 3.3 | 23 |
| 116 | Different MDSC Activity of G-CSF/Dexamethasone Mobilized Neutrophils: Benefits to the Patient?. Frontiers in Oncology, 2020, 10, 1110. | 1.3 | 4 |
| 117 | Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology, Immunotherapy, 2020, 69, 2403-2408. | 2.0 | 10 |
| 118 | Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34, 3413-3419. | 3.3 | 42 |
| 119 | The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer, 2020, 20, 738. | 1.1 | 9 |
| 120 | Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. Cancers, 2020, 12, 2237. | 1.7 | 71 |
| 121 | Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065. | | 70 |
| 122 | Germline genomes have a dominantâ€heritable contribution to cancer immune evasion and immunotherapy response. Quantitative Biology, 2020, 8, 216-227. | 0.3 | 2 |
| 123 | Biomarkers for immune checkpoint inhibitors in non-small-cellÂlung cancer. Biomarkers in Medicine, 2020, 14, 929-932. | 0.6 | 0 |
| 124 | COVID-19 and Cardiovascular Health Among Patients with Cancer. Current Cardiology Reports, 2020, 22, 171. | 1.3 | 8 |
| 125 | Inducing multiple antibodies to treat squamous cell esophageal carcinoma. BMC Cancer, 2020, 20, 1007. | 1.1 | 3 |
| 126 | Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. Toxins, 2020, 12, 658. | 1.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | RNA-electroporated T cells for cancer immunotherapy. OncoImmunology, 2020, 9, 1792625. | 2.1 | 6 |
| 128 | Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opinion on Therapeutic Targets, 2020, 24, 1251-1262. | 1.5 | 16 |
| 129 | Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2020, 5, 250. | 7.1 | 86 |
| 130 | Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. Cancers, 2020, 12, 3052. | 1.7 | 13 |
| 131 | Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules, 2020, 25, 4831. | 1.7 | 69 |
| 132 | Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. , 2020, 8, e001141. | | 31 |
| 133 | Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy, 2020, 12, 1183-1193. | 1.0 | 12 |
| 134 | Immune infiltrating cells in duodenal cancers. Journal of Translational Medicine, 2020, 18, 340. | 1.8 | 3 |
| 135 | Targeting TANK-binding kinase 1 (TBK1) in cancer. Expert Opinion on Therapeutic Targets, 2020, 24, 1065-1078. | 1.5 | 26 |
| 136 | In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by Î±-Mannosyl-Functionalized Cationic Nanohydrogel Particles. Cells, 2020, 9, 1905. | 1.8 | 36 |
| 137 | Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. Journal of Vascular and Interventional Radiology, 2020, 31, 1233-1241. | 0.2 | 11 |
| 138 | Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407. | 1.9 | 125 |
| 139 | Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncology, The, 2020, 21, e419-e430. | 5.1 | 128 |
| 140 | Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. Biomedicines, 2020, 8, 327. | 1.4 | 9 |
| 141 | The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines, 2020, 8, 529. | 2.1 | 9 |
| 142 | VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. In Vivo, 2020, 34, 2641-2646. | 0.6 | 15 |
| 143 | Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. BMJ Case Reports, 2020, 13, e235265. | 0.2 | 18 |
| 144 | CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. Frontiers in Immunology, 2020, 11, 1568. | 2.2 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Leptomeningeal Carcinomatosis. Neurosurgery Clinics of North America, 2020, 31, 613-625. | 0.8 | 21 |
| 146 | Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. Pharmaceutics, 2020, 12, 754. | 2.0 | 12 |
| 147 | Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. Pharmaceutics, 2020, 12, 758. | 2.0 | 6 |
| 148 | <p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 7229-7241. | 1.0 | 12 |
| 149 | Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives. Cancers, 2020, 12, 2334. | 1.7 | 15 |
| 150 | Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 5869-5878. | 3.2 | 131 |
| 151 | Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells, 2020, 9, 1896. | 1.8 | 73 |
| 152 | Repositioning of Immunomodulators: A Ray of Hope for Alzheimerâ€™s Disease?. Frontiers in Neuroscience, 2020, 14, 614643. | 1.4 | 16 |
| 153 | Current Trends in Cancer Immunotherapy. Biomedicines, 2020, 8, 621. | 1.4 | 34 |
| 154 | Resveratrol Activates Natural Killer Cells through Akt- and mTORC2-Mediated c-Myb Upregulation. International Journal of Molecular Sciences, 2020, 21, 9575. | 1.8 | 16 |
| 155 | The pancancer landscape of Wnt family expression reveals potential biomarkers in urinary system tumors. Cancer Gene Therapy, 2020, 28, 1035-1045. | 2.2 | 1 |
| 156 | Immune gene therapy of cancer. Turkish Journal of Medical Sciences, 2020, 50, 1679-1690. | 0.4 | 9 |
| 157 | Progressive multifocal leukoencephalopathy treated with interleukin-7. Clinical Infection in Practice, 2020, 7-8, 100049. | 0.2 | 2 |
| 158 | Immune checkpoint markers and antiâ€CD20â€mediated NK cell activation. Journal of Leukocyte Biology, 2020, 110, 723-733. | 1.5 | 2 |
| 159 | Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. American Journal of Roentgenology, 2021, 217, 613-622. | 1.0 | 9 |
| 160 | TGF-Î² Mediated Immune Evasion in Cancerâ€”Spotlight on Cancer-Associated Fibroblasts. Cancers, 2020, 12, 3650. | 1.7 | 37 |
| 161 | Living with Metastatic Cancer: A Roadmap for Future Research. Cancers, 2020, 12, 3684. | 1.7 | 26 |
| 162 | Acquired lipodystrophy associated with immune checkpoint inhibitors. Melanoma Research, 2020, 30, 599-602. | 0.6 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology. Epigenomes, 2020, 4, 22. | 0.8 | 6 |
| 164 | Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nature Communications, 2020, 11, 5650. | 5.8 | 207 |
| 165 | Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. Journal of Personalized Medicine, 2020, 10, 208. | 1.1 | 23 |
| 166 | The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Frontiers in Oncology, 2020, 10, 524205. | 1.3 | 31 |
| 167 | Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis. BMC Cancer, 2020, 20, 1062. | 1.1 | 27 |
| 168 | Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents. Current Clinical Microbiology Reports, 2020, 7, 142-149. | 1.8 | 12 |
| 169 | Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. Journal of Vascular and Interventional Radiology, 2020, 31, 1740-1744.e9. | 0.2 | 5 |
| 170 | Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy. Molecular Therapy - Oncolytics, 2020, 17, 241-249. | 2.0 | 60 |
| 171 | The advent of de novo proteins for cancer immunotherapy. Current Opinion in Chemical Biology, 2020, 56, 119-128. | 2.8 | 15 |
| 172 | T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology, 2020, 129, e97. | 3.6 | 7 |
| 173 | HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment. Journal of Cancer, 2020, 11, 4059-4072. | 1.2 | 65 |
| 174 | Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers, 2020, 12, 1181. | 1.7 | 69 |
| 175 | Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. British Journal of Clinical Pharmacology, 2020, 86, 1753-1768. | 1.1 | 7 |
| 176 | Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology, 2020, 85, 106628. | 1.7 | 14 |
| 177 | Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation. ACS Applied Materials & Interfaces, 2020, 12, 28047-28056. | 4.0 | 30 |
| 178 | Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nature Communications, 2020, 11, 2739. | 5.8 | 210 |
| 179 | Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors. Journal of Infectious Diseases, 2020, 222, 1902-1909. | 1.9 | 33 |
| 180 | Functional and metabolic targeting of natural killer cells to solid tumors. Cellular Oncology (Dordrecht), 2020, 43, 577-600. | 2.1 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology and Oncology, 2020, 13, 45. | 6.9 | 105 |
| 182 | Recombinant human ulinastatin improves immune dysfunction of dendritic cells in septic mice by inhibiting endoplasmic reticulum stress-related apoptosis. International Immunopharmacology, 2020, 85, 106643. | 1.7 | 7 |
| 183 | The immunoregulatory function of polyphenols: implications in cancer immunity. Journal of Nutritional Biochemistry, 2020, 85, 108428. | 1.9 | 20 |
| 184 | Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198. | 0.4 | 19 |
| 185 | Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Medicine, 2020, 12, 47. | 3.6 | 107 |
| 186 | Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers, 2020, 12, 1315. | 1.7 | 18 |
| 187 | Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Molecular Cell, 2020, 78, 1019-1033. | 4.5 | 450 |
| 188 | Old dogs, new trick: classic cancer therapies activate cGAS. Cell Research, 2020, 30, 639-648. | 5.7 | 104 |
| 189 | Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. Expert Opinion on Drug Discovery, 2020, 15, 1223-1232. | 2.5 | 8 |
| 190 | Outcomes of immunomodulatory and biologic therapy in people living with HIV. Aids, 2020, 34, 1171-1179. | 1.0 | 7 |
| 191 | NF-Î¹B and Its Role in Checkpoint Control. International Journal of Molecular Sciences, 2020, 21, 3949. | 1.8 | 45 |
| 192 | Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treatment Reviews, 2020, 88, 102030. | 3.4 | 44 |
| 193 | Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 4030. | 1.8 | 7 |
| 194 | Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. Journal of Experimental and Clinical Cancer Research, 2020, 39, 112. | 3.5 | 158 |
| 195 | Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 2247-2257. | 2.0 | 14 |
| 196 | Advances in tissue-based imaging: impact on oncology research and clinical practice. Expert Review of Molecular Diagnostics, 2020, 20, 1027-1037. | 1.5 | 5 |
| 197 | Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. Frontiers in Immunology, 2020, 11, 1469. | 2.2 | 58 |
| 198 | pHâ€Responsive STINGâ€Activating DNA Nanovaccines for Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000083. | 1.6 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Immunometabolism: new insights and lessons from antigen-directed cellular immune responses. Seminars in Immunopathology, 2020, 42, 279-313. | 2.8 | 37 |
| 200 | Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy. Frontiers in Bioengineering and Biotechnology, 2020, 8, 348. | 2.0 | 4 |
| 201 | Small molecules targeting the innate immune cGASâ€'STINGâ€'TBK1 signaling pathway. Acta Pharmaceutica Sinica B, 2020, 10, 2272-2298. | 5.7 | 147 |
| 202 | <p>High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma</p>. OncoTargets and Therapy, 2020, Volume 13, 1757-1765. | 1.0 | 8 |
| 203 | Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer, 2020, 143, 19-26. | 0.9 | 81 |
| 204 | The immune checkpoints Cytotoxic T lymphocyte antigenâ€4 and Lymphocyte activation geneâ€3 expression is upâ€regulated in acute myeloid leukemia. Hla, 2020, 96, 3-12. | 0.4 | 17 |
| 205 | A Fatal Case of Pembrolizumab-Induced Myocarditis in Nonâ€“Small Cell LungÂCancer. JACC: Case Reports, 2020, 2, 426-430. | 0.3 | 7 |
| 206 | Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors. Molecular Therapy - Oncolytics, 2020, 17, 47-60. | 2.0 | 35 |
| 207 | A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation. Cancer Immunology Research, 2020, 8, 596-608. | 1.6 | 28 |
| 208 | Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Cancers, 2020, 12, 767. | 1.7 | 2 |
| 209 | Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Nonâ€Small Cell Lung Cancer. Advanced Science, 2020, 7, 1903410. | 5.6 | 30 |
| 210 | Next-generation stem cells â€" ushering in a new era of cell-based therapies. Nature Reviews Drug Discovery, 2020, 19, 463-479. | 21.5 | 161 |
| 211 | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration. Neurotherapeutics, 2020, 17, 955-965. | 2.1 | 17 |
| 212 | Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology, 2020, 8, 141. | 2.0 | 35 |
| 213 | Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy. Cells, 2020, 9, 565. | 1.8 | 28 |
| 214 | Determinants of Resistance to Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 1594. | 1.8 | 39 |
| 215 | Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research, 2020, 155, 104740. | 3.1 | 46 |
| 216 | New tools to prevent cancer growth and spread: a â€˜Cleverâ€™ approach. British Journal of Cancer, 2020, 123, 501-509. | 2.9 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Functional categories of immune inhibitory receptors. Nature Reviews Immunology, 2020, 20, 771-780. | 10.6 | 60 |
| 218 | Exploiting Cancerâ€™s Tactics to Make Cancer a Manageable Chronic Disease. Cancers, 2020, 12, 1649. | 1.7 | 3 |
| 219 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821. | 4.8 | 1,136 |
| 220 | On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. , 2020, 8, e001145. | | 48 |
| 221 | Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. Frontiers in Immunology, 2020, 11, 1184. | 2.2 | 65 |
| 222 | Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges. Cancers, 2020, 12, 1699. | 1.7 | 27 |
| 223 | Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140. | 0.9 | 62 |
| 224 | Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers. Cancers, 2020, 12, 1802. | 1.7 | 14 |
| 225 | Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 635-648. | 8.2 | 172 |
| 226 | Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093611. | 1.4 | 28 |
| 227 | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427. | 1.8 | 67 |
| 228 | Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours. Cell Proliferation, 2020, 53, e12865. | 2.4 | 43 |
| 229 | Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?. Cells, 2020, 9, 1525. | 1.8 | 13 |
| 230 | Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. Genes, 2020, 11, 703. | 1.0 | 14 |
| 231 | Soluble immune checkpoints CTLAâ€4, HLAâ€G, PDâ€1, and PDâ€L1 are associated with endometriosisâ€related infertility. American Journal of Reproductive Immunology, 2020, 84, e13296. | 1.2 | 19 |
| 232 | Regulatory lymphocytes: the dice that resolve the tumor endgame. Applied Cancer Research, 2020, 40, . | 1.0 | 7 |
| 233 | Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. Cancers, 2020, 12, 1826. | 1.7 | 46 |
| 234 | Organoid technology and applications in cancer immunotherapy and precision medicine. Current Opinion in Biotechnology, 2020, 65, 242-247. | 3.3 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacological Research, 2020, 153, 104683. | 3.1 | 269 |
| 236 | Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody. RSC Advances, 2020, 10, 8074-8079. | 1.7 | 13 |
| 237 | High-dose vitamin C enhances cancer immunotherapy. Science Translational Medicine, 2020, 12, . | 5.8 | 143 |
| 238 | Expanding the reach of medical physics: Immunotherapy should be included as part of the curriculum for medical physics education and training. Journal of Applied Clinical Medical Physics, 2020, 21, 6-10. | 0.8 | 0 |
| 239 | Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Research, 2020, 80, 1615-1623. | 0.4 | 120 |
| 240 | Identification of Antigenic Targets. Trends in Cancer, 2020, 6, 299-318. | 3.8 | 6 |
| 241 | Cholangiocarcinoma: novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 345-357. | 1.5 | 25 |
| 242 | Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Review of Precision Medicine and Drug Development, 2020, 5, 59-65. | 0.4 | 13 |
| 243 | Analytical Performance of an Immunoprofiling Assay Based on RNA Models. Journal of Molecular Diagnostics, 2020, 22, 555-570. | 1.2 | 6 |
| 244 | Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins. Seminars in Immunology, 2020, 47, 101392. | 2.7 | 5 |
| 245 | Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biology, 2020, 18, e3000591. | 2.6 | 58 |
| 246 | Peptide-based targeting of immunosuppressive cells in cancer. Bioactive Materials, 2020, 5, 92-101. | 8.6 | 41 |
| 247 | Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. International Journal of Molecular Sciences, 2020, 21, 597. | 1.8 | 58 |
| 248 | Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229. | 1.8 | 311 |
| 249 | Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Scientific Reports, 2020, 10, 643. | 1.6 | 124 |
| 250 | Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells. Frontiers in Immunology, 2019, 10, 3122. | 2.2 | 7 |
| 251 | Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. Targeted Oncology, 2020, 15, 25-35. | 1.7 | 25 |
| 252 | Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. Journal of Translational Medicine, 2020, 18, 49. | 1.8 | 114 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Cancer Immunotherapy: An Effective Tool in Cancer Control and Treatment. Current Cancer Therapy Reviews, 2020, 16, 62-69. | 0.2 | 5 |
| 254 | Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047. | 1.7 | 95 |
| 255 | A review of the imaging manifestations of immune check point inhibitor toxicities. Clinical Imaging, 2020, 64, 70-79. | 0.8 | 9 |
| 256 | FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Clinical Cancer Research, 2020, 26, 4154-4167. | 3.2 | 44 |
| 257 | Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers, 2020, 12, 751. | 1.7 | 66 |
| 258 | Development and functional analysis of an anticancer Tâ€cell medicine with immune checkpoint inhibitory ability. IUBMB Life, 2020, 72, 1649-1658. | 1.5 | 2 |
| 259 | Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting. Cancers, 2020, 12, 915. | 1.7 | 1 |
| 260 | FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Research and Treatment, 2020, 181, 331-338. | 1.1 | 25 |
| 261 | Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. Current Opinion in Oncology, 2020, 32, 203-209. | 1.1 | 8 |
| 262 | Towards Physiologically and Tightly Regulated Vectored Antibody Therapies. Cancers, 2020, 12, 962. | 1.7 | 13 |
| 263 | microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. International Journal of Molecular Sciences, 2020, 21, 2805. | 1.8 | 17 |
| 264 | Talkinâ€™ Toxins: From Coleyâ€™s to Modern Cancer Immunotherapy. Toxins, 2020, 12, 241. | 1.5 | 47 |
| 265 | Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 150, 102966. | 2.0 | 45 |
| 266 | How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. Frontiers in Physiology, 2020, 11, 154. | 1.3 | 27 |
| 267 | Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Review of Clinical Pharmacology, 2020, 13, 403-421. | 1.3 | 7 |
| 268 | Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. , 2020, 8, e000613. | | 15 |
| 269 | Comparison of Immune Microenvironment Between Colon and Liver Metastatic Tissue in Colon Cancer Patients with Liver Metastasis. Digestive Diseases and Sciences, 2021, 66, 474-482. | 1.1 | 12 |
| 270 | Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology, 2021, 87, 237-255. | 1.1 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Pathology of triple negative breast cancer. Seminars in Cancer Biology, 2021, 72, 136-145. | 4.3 | 118 |
| 272 | Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer. Clinical and Translational Oncology, 2021, 23, 418-423. | 1.2 | 31 |
| 273 | Impact of pharmacist-managed immune checkpoint inhibitor toxicities. Journal of Oncology Pharmacy Practice, 2021, 27, 596-600. | 0.5 | 11 |
| 274 | Immune Checkpoint Inhibitorâ€"Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Archives of Pathology and Laboratory Medicine, 2021, 145, 191-200. | 1.2 | 23 |
| 275 | Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 2021, 29, 505-520. | 3.7 | 48 |
| 276 | Characteristic pathological features of keratinocyte death in a case of Stevensâ€"Johnson syndrome manifested by an immune checkpoint inhibitor. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e142-e145. | 1.3 | 8 |
| 277 | Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. , 2021, 217, 107662. | | 18 |
| 278 | Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. Clinical and Translational Oncology, 2021, 23, 110-121. | 1.2 | 9 |
| 279 | Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. Trends in Molecular Medicine, 2021, 27, 75-90. | 3.5 | 5 |
| 280 | Use of an antiâ€CD200â€blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology, 2021, 193, 155-159. | 1.2 | 15 |
| 281 | Monoclonal antibodies as an addition to current myeloma therapy strategies. Expert Review of Anticancer Therapy, 2021, 21, 33-43. | 1.1 | 5 |
| 282 | Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. Cancer Immunology, Immunotherapy, 2021, 70, 935-944. | 2.0 | 23 |
| 283 | Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101525. | 0.7 | 0 |
| 284 | Immune Checkpoint Inhibitorâ€"Associated Autoimmune Encephalitis. Journal of the Academy of Consultation-Liaison Psychiatry, 2021, 62, 115-118. | 0.2 | 3 |
| 285 | Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188483. | 3.3 | 7 |
| 286 | Bidirectional and dynamic interaction between the microbiota and therapeutic resistance in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188484. | 3.3 | 11 |
| 287 | Cancer evolution: A means by which tumors evade treatment. Biomedicine and Pharmacotherapy, 2021, 133, 111016. | 2.5 | 20 |
| 288 | AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence. Expert Opinion on Investigational Drugs, 2021, 30, 5-11. | 1.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors. Frontiers in Oncology, 2020, 10, 574860. | 1.3 | 13 |
| 290 | The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160. | 2.0 | 26 |
| 291 | Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL. Leukemia and Lymphoma, 2021, 62, 992-994. | 0.6 | 3 |
| 292 | Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy. Journal of Controlled Release, 2021, 330, 1168-1177. | 4.8 | 17 |
| 293 | Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. Journal of Thoracic Oncology, 2021, 16, 381-394. | 0.5 | 12 |
| 294 | Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis. Clinical and Experimental Immunology, 2021, 204, 78-95. | 1.1 | 10 |
| 295 | Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. BioDrugs, 2021, 35, 61-73. | 2.2 | 1 |
| 296 | TIM-3 pathway dysregulation and targeting in cancer. Expert Review of Anticancer Therapy, 2021, 21, 523-534. | 1.1 | 54 |
| 297 | A Systematic Review of Immune Checkpoint Inhibitorâ€“Associated Glomerular Disease. Kidney International Reports, 2021, 6, 66-77. | 0.4 | 84 |
| 298 | Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation. International Journal of Cancer, 2021, 148, 1808-1820. | 2.3 | 1 |
| 299 | Emerging Immunotherapies in the Treatment of Brain Metastases. Oncologist, 2021, 26, 231-241. | 1.9 | 29 |
| 300 | Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1075-1088. | 2.0 | 18 |
| 301 | Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells. Cancer Letters, 2021, 497, 212-220. | 3.2 | 30 |
| 302 | ADARs, RNA editing and more in hematological malignancies. Leukemia, 2021, 35, 346-359. | 3.3 | 10 |
| 303 | Advances in Magnetic Nanoparticleâ€Mediated Cancer Immuneâ€Theranostics. Advanced Healthcare Materials, 2021, 10, e2001451. | 3.9 | 59 |
| 304 | Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opinion on Biological Therapy, 2021, 21, 311-322. | 1.4 | 10 |
| 305 | Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Modern Pathology, 2021, 34, 408-416. | 2.9 | 22 |
| 306 | The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events. Journal of Pharmacy Practice, 2021, 34, 386-396. | 0.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Machine and deep learning approaches for cancer drug repurposing. Seminars in Cancer Biology, 2021, 68, 132-142. | 4.3 | 122 |
| 308 | Immune checkpoint molecules: â€œnewâ€•kids on the block of skin photoimmunology. Genes and Diseases, 2021, 8, 1-5. | 1.5 | 0 |
| 309 | Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. Clinical and Translational Immunology, 2021, 10, e1267. | 1.7 | 4 |
| 310 | Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22. | | 2 |
| 311 | Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play. International Journal of Molecular Sciences, 2021, 22, 1071. | 1.8 | 8 |
| 312 | Antibody-Based Molecular Imaging. , 2021, , 547-562. | | 0 |
| 313 | Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. OncoImmunology, 2021, 10, 1958590. | 2.1 | 16 |
| 314 | T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Frontiers in Immunology, 2020, 11, 612244. | 2.2 | 31 |
| 315 | Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research, 2021, 27, 2168-2178. | 3.2 | 67 |
| 316 | Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. , 2021, , 271-308. | | 0 |
| 317 | Intraepithelial Lymphocytes Suppress Intestinal Tumor Growth by Cell-to-Cell Contact via CD103/E-Cadherin Signal. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1483-1503. | 2.3 | 14 |
| 318 | Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients. Iraqi Journal of Hematology, 2021, 10, 1. | 0.0 | 2 |
| 319 | IFN-Î³ and CD38 in Hyperprogressive Cancer Development. Cancers, 2021, 13, 309. | 1.7 | 17 |
| 320 | Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype. IScience, 2021, 24, 102016. | 1.9 | 32 |
| 321 | Emerging role of circulating tumor cells in immunotherapy. Theranostics, 2021, 11, 8057-8075. | 4.6 | 19 |
| 322 | The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review. Cancer Control, 2021, 28, 107327482199743. | 0.7 | 30 |
| 323 | The Multiple Potential Biomarkers for Predicting Immunotherapy Responseâ€"Finding the Needle in the Haystack. Cancers, 2021, 13, 277. | 1.7 | 16 |
| 324 | The Road to Effective Cancer Immunotherapyâ€"A Computational Perspective on Tumor Epitopes in Anti-Cancer Immunotherapy. , 2021, , 593-607. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584. | 1.5 | 12 |
| 326 | Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 334. | 1.7 | 44 |
| 327 | Methods to Study Posttranslational Modification Patterns in Cytotoxic T-Cells and Cancer. Methods in Molecular Biology, 2021, 2325, 137-153. | 0.4 | 1 |
| 328 | Chelerythrine and Chelidonine Decrease Extracellular Adenosine Improving Cd8 <sup>+</sup> T Anti-Tumor Immunity. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 329 | Epithelial and Immune Cell Responses to Helicobacter pylori That Shape the Gastric Tumor Microenvironment. Physiology in Health and Disease, 2021, , 155-197. | 0.2 | 0 |
| 330 | PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer. Cells, 2021, 10, 229. | 1.8 | 8 |
| 331 | Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy. Cells, 2021, 10, 231. | 1.8 | 34 |
| 332 | LncRNA as Cancer Biomarkers. Methods in Molecular Biology, 2021, 2348, 27-41. | 0.4 | 14 |
| 333 | CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics, 2021, 11, 7175-7187. | 4.6 | 34 |
| 334 | Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Advances in Experimental Medicine and Biology, 2021, 1330, 33-54. | 0.8 | 3 |
| 335 | Summarizing RNA-Seq Data or Differentially Expressed Genes Using Gene Set, Network, or Pathway Analysis. Methods in Molecular Biology, 2021, 2284, 147-179. | 0.4 | 4 |
| 336 | Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Annals of Translational Medicine, 2021, 9, 129-129. | 0.7 | 24 |
| 337 | PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma. OncoImmunology, 2021, 10, 1960729. | 2.1 | 8 |
| 338 | NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. Frontiers in Oncology, 2020, 10, 574937. | 1.3 | 29 |
| 339 | Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nature Protocols, 2021, 16, 1331-1342. | 5.5 | 48 |
| 340 | Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. Frontiers in Immunology, 2021, 12, 631483. | 2.2 | 5 |
| 341 | Bladder cancer cellâ€intrinsic PDâ€L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Medicine, 2021, 10, 2137-2152. | 1.3 | 26 |
| 342 | Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World Journal of Clinical Oncology, 2021, 12, 103-114. | 0.9 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Immune checkpoint inhibitor-induced takotsubo syndrome and diabetic ketoacidosis: rare reactions. BMJ Case Reports, 2021, 14, e237217. | 0.2 | 16 |
| 344 | A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. Nature Communications, 2021, 12, 1087. | 5.8 | 62 |
| 345 | Stimulation and Suppression of the Innate Immune System through Nanotechnology. ACS Applied Nano Materials, 2021, 4, 2303-2316. | 2.4 | 5 |
| 346 | Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Seminars in Cancer Biology, 2022, 78, 78-89. | 4.3 | 16 |
| 347 | Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Nonâ€“small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 627089. | 1.2 | 9 |
| 348 | Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics, 2021, 13, 257. | 2.0 | 7 |
| 349 | In Vitro Suppression of T Cell Proliferation Is a Conserved Function of Primary and Immortalized Human Cancer-Associated Fibroblasts. International Journal of Molecular Sciences, 2021, 22, 1827. | 1.8 | 11 |
| 350 | Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 860. | 1.7 | 37 |
| 351 | Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?. International Journal of Molecular Sciences, 2021, 22, 2142. | 1.8 | 6 |
| 352 | PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Clinical and Translational Oncology, 2021, 23, 1630-1636. | 1.2 | 14 |
| 353 | Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clinical Cancer Research, 2021, 27, 2755-2763. | 3.2 | 29 |
| 354 | Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Frontiers in Oncology, 2020, 10, 600573. | 1.3 | 100 |
| 355 | Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. Nature Communications, 2021, 12, 975. | 5.8 | 26 |
| 356 | Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. Journal of Medical Case Reports, 2021, 15, 72. | 0.4 | 1 |
| 357 | Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?. Frontiers in Pharmacology, 2021, 12, 572845. | 1.6 | 6 |
| 358 | Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Scientific Reports, 2021, 11, 3750. | 1.6 | 22 |
| 359 | Immunogenic Cell Death Inducing Fluorinated Mitochondriaâ€Disrupting Helical Polypeptide Synergizes with PDâ€L1 Immune Checkpoint Blockade. Advanced Science, 2021, 8, 2001308. | 5.6 | 31 |
| 360 | The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro-Oncology, 2021, 23, 1261-1272. | 0.6 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Neurological Complications of Targeted Therapies and Immunotherapies for Cancer. Current Treatment Options in Neurology, 2021, 23, 1. | 0.7 | 3 |
| 362 | Multiple endocrinopathies, hypercalcaemia and pancreatitis following combined immune checkpoint inhibitor use- case report and review of literature. BMC Endocrine Disorders, 2021, 21, 33. | 0.9 | 5 |
| 363 | PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation. Cancers, 2021, 13, 555. | 1.7 | 18 |
| 364 | Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma. Cancers, 2021, 13, 1044. | 1.7 | 8 |
| 365 | Surprising impact of stromal TILâ€™s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer, 2021, 153, 81-89. | 0.9 | 42 |
| 366 | Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Annals of Translational Medicine, 2021, 9, 465-465. | 0.7 | 14 |
| 367 | Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer. , 2021, 9, e001610. | | 27 |
| 369 | Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology, 2021, 7, 10. | 0.8 | 12 |
| 370 | Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors. Clinical Transplantation, 2021, 35, e14264. | 0.8 | 3 |
| 371 | Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics, 2021, 5, 326-337. | 1.0 | 4 |
| 372 | Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. Frontiers in Endocrinology, 2021, 12, 624686. | 1.5 | 13 |
| 373 | Mucosal Associated Invariant T Cells in Cancer-Friend or Foe?. Cancers, 2021, 13, 1582. | 1.7 | 11 |
| 374 | Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 641469. | 1.8 | 76 |
| 375 | Next generation of immune checkpoint inhibitors and beyond. Journal of Hematology and Oncology, 2021, 14, 45. | 6.9 | 293 |
| 376 | Correlation Between TIGIT Expression on CD8+ T Cells and Higher Cytotoxic Capacity. Journal of Infectious Diseases, 2021, 224, 1599-1604. | 1.9 | 13 |
| 377 | Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. Npj Precision Oncology, 2021, 5, 17. | 2.3 | 23 |
| 378 | A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mammalian Genome, 2021, 32, 223-231. | 1.0 | 17 |
| 379 | Endokrynologiczne powikÅ‚ania nowych terapii przeciwnowotworowych. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 191-198. | 0.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 380 | Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. Cancer Immunology Research, 2021, 9, 255-260. | 1.6 | 16 |
| 381 | Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Frontiers in Oncology, 2021, 11, 589680. | 1.3 | 23 |
| 382 | Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Scientific Reports, 2021, 11, 6956. | 1.6 | 3 |
| 383 | Emerging nanotechnological strategies to reshape tumor microenvironment for enhanced therapeutic outcomes of cancer immunotherapy. Biomedical Materials (Bristol), 2021, 16, 042001. | 1.7 | 6 |
| 384 | Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 161-172. | 1.6 | 52 |
| 385 | Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Molecular Therapy - Oncolytics, 2021, 20, 508-518. | 2.0 | 21 |
| 386 | MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines, 2021, 9, 318. | 1.4 | 7 |
| 387 | Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer. Translational Andrology and Urology, 2021, 10, 1229-1240. | 0.6 | 16 |
| 388 | The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. European Journal of Pharmacology, 2021, 896, 173921. | 1.7 | 57 |
| 389 | Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors. Endocrinology and Metabolism, 2021, 36, 413-423. | 1.3 | 24 |
| 390 | Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics, 2021, 13, 520. | 2.0 | 25 |
| 391 | Embracing nanomaterials' interactions with the innate immune system. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1719. | 3.3 | 10 |
| 392 | The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF). EBioMedicine, 2021, 66, 103325. | 2.7 | 16 |
| 393 | Trials and tribulations of pancreatic cancer immunotherapy. Cancer Letters, 2021, 504, 1-14. | 3.2 | 37 |
| 394 | Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immuneâ€Based Combination Therapy. Macromolecular Bioscience, 2021, 21, e2100039. | 2.1 | 34 |
| 395 | Challenges and perspectives for immunotherapy inÂoesophageal cancer: A look to the future (Review). International Journal of Molecular Medicine, 2021, 47, . | 1.8 | 3 |
| 396 | An Immune Checkpoint-Related Gene Signature for Predicting Survival of Pediatric Acute Myeloid Leukemia. Journal of Oncology, 2021, 2021, 1-14. | 0.6 | 21 |
| 397 | Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma. Frontiers in Oncology, 2021, 11, 654350. | 1.3 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 398 | Construction of an immuneâ€related LncRNA signature with prognostic significance for bladder cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 4326-4339. | 1.6 | 19 |
| 399 | CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from Î±PD-L1 and include tissue-selective Î³Î´ T cell activation. , 2021, 9, e002051. | | 12 |
| 400 | Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma. Cancers, 2021, 13, 2167. | 1.7 | 11 |
| 401 | Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. Journal of Controlled Release, 2021, 332, 109-126. | 4.8 | 33 |
| 402 | Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 648580. | 2.2 | 11 |
| 403 | Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. Cancer Immunology, Immunotherapy, 2021, 70, 3303-3312. | 2.0 | 5 |
| 404 | Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist, 2021, 26, e1216-e1225. | 1.9 | 26 |
| 405 | How to use liquid biopsies to treat patients with cancer. ESMO Open, 2021, 6, 100060. | 2.0 | 43 |
| 406 | Role of the nervous system in cancers: a review. Cell Death Discovery, 2021, 7, 76. | 2.0 | 59 |
| 407 | Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 646874. | 2.2 | 6 |
| 408 | Changing the History of Prostate Cancer with New Targeted Therapies. Biomedicines, 2021, 9, 392. | 1.4 | 16 |
| 409 | Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells, 2021, 10, 1006. | 1.8 | 45 |
| 410 | Addressing resistance to immune checkpoint inhibitor therapy:Âan urgent unmet need. Future Oncology, 2021, 17, 1401-1439. | 1.1 | 17 |
| 411 | Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. Scientific Reports, 2021, 11, 7490. | 1.6 | 8 |
| 412 | Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Frontiers in Immunology, 2021, 12, 643255. | 2.2 | 6 |
| 413 | Strategies for monitoring cellâ€“cell interactions. Nature Chemical Biology, 2021, 17, 641-652. | 3.9 | 59 |
| 414 | Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators. Current Cancer Drug Targets, 2021, 21, 353-359. | 0.8 | 6 |
| 415 | Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging. Frontiers in Immunology, 2021, 12, 687673. | 2.2 | 59 |

| # | Article | IF | Citations |
|---|---|---|---|
| 416 | Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors. Neurology, 2021, 97, e191-e202. | 1.5 | 26 |
| 417 | Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. BMC Cancer, 2021, 21, 645. | 1.1 | 70 |
| 418 | Clinical Insights Into Novel Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 681320. | 1.6 | 76 |
| 419 | Cancer microenvironment and genomics: evolution in process. Clinical and Experimental Metastasis, 2022, 39, 85-99. | 1.7 | 11 |
| 420 | An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. Biomolecules, 2021, 11, 785. | 1.8 | 9 |
| 421 | Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. Cancers, 2021, 13, 2498. | 1.7 | 23 |
| 422 | The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer. Breast Cancer Research and Treatment, 2021, 187, 635-645. | 1.1 | 3 |
| 423 | Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations. Expert Opinion on Therapeutic Targets, 2021, 25, 347-363. | 1.5 | 25 |
| 424 | Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route. Journal of Medicinal Chemistry, 2021, 64, 6902-6923. | 2.9 | 26 |
| 425 | Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials, 2021, 272, 120791. | 5.7 | 83 |
| 426 | Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. Genomics, Proteomics and Bioinformatics, 2021, 19, 191-207. | 3.0 | 5 |
| 427 | Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma. Oncology Letters, 2021, 22, 554. | 0.8 | 29 |
| 428 | Organic optical agents for image-guided combined cancer therapy. Biomedical Materials (Bristol), 2021, 16, 042009. | 1.7 | 5 |
| 429 | The abscopal effect of radiation therapy. Future Oncology, 2021, 17, 1683-1694. | 1.1 | 61 |
| 431 | Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma. Frontiers in Molecular Biosciences, 2021, 8, 629330. | 1.6 | 3 |
| 432 | Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)â€"insights of people affected by cancer and healthcare professionals: a qualitative study protocol. BMJ Open, 2021, 11, e043750. | 0.8 | 3 |
| 433 | Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity. Cancers, 2021, 13, 2735. | 1.7 | 21 |
| 434 | Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. Advances in Oncology, 2021, 1, 85-95. | 0.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 435 | TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Frontiers in Immunology, 2021, 12, 637146. | 2.2 | 32 |
| 436 | Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392. | | 9 |
| 437 | Comprehensive Profiling Reveals Distinct Microenvironment and Metabolism Characterization of Lung Adenocarcinoma. Frontiers in Genetics, 2021, 12, 619821. | 1.1 | 3 |
| 438 | Recent Progress in Dendritic Cell-Based Cancer Immunotherapy. Cancers, 2021, 13, 2495. | 1.7 | 26 |
| 439 | Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Network Open, 2021, 4, e218065. | 2.8 | 31 |
| 440 | The influence of monoclonal antibodies for cancer treatment on the endocrine system. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 317-327. | 0.1 | 0 |
| 441 | Immunotherapies targeting stimulatory pathways and beyond. Journal of Hematology and Oncology, 2021, 14, 78. | 6.9 | 23 |
| 442 | Cancer Salt Nostalgia. Cells, 2021, 10, 1285. | 1.8 | 5 |
| 443 | Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treatment Reviews, 2021, 101, 102227. | 3.4 | 42 |
| 444 | Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 4843. | 1.8 | 8 |
| 445 | Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. Drug Resistance Updates, 2021, 56, 100752. | 6.5 | 35 |
| 446 | Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. Cancers, 2021, 13, 2302. | 1.7 | 2 |
| 447 | The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunology, Immunotherapy, 2021, 70, 3629-3642. | 2.0 | 11 |
| 448 | Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 3244-3261. | 5.7 | 41 |
| 449 | Nanotechnology synergized immunoengineering for cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 72-101. | 2.0 | 8 |
| 450 | Integration of Salmonella into Combination Cancer Therapy. Cancers, 2021, 13, 3228. | 1.7 | 15 |
| 451 | Mismatch repair deficiency is rare in bone and soft tissue tumors. Histopathology, 2021, 79, 509-520. | 1.6 | 18 |
| 452 | Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treatment Reviews, 2021, 97, 102172. | 3.4 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 453 | Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2021, 5, bvab100. | 0.1 | 9 |
| 454 | TIGIT modulates sepsis-induced immune dysregulation in mice with preexisting malignancy. JCI Insight, 2021, 6, . | 2.3 | 14 |
| 455 | Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Frontiers in Endocrinology, 2021, 12, 649863. | 1.5 | 24 |
| 456 | Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology. Small Structures, 2021, 2, 2100026. | 6.9 | 7 |
| 457 | The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy. Frontiers in Pharmacology, 2021, 12, 687399. | 1.6 | 32 |
| 458 | Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2793. | 1.7 | 8 |
| 459 | Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. ELife, 2021, 10, . | 2.8 | 40 |
| 460 | MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3. Cell Death Discovery, 2021, 7, 145. | 2.0 | 18 |
| 461 | Bioinformatics: A beacon of hope in identifying molecular target. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 496-498. | 0.6 | 2 |
| 462 | Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Frontiers in Oncology, 2021, 11, 684098. | 1.3 | 41 |
| 463 | DNA Nanotechnologyâ€Based Biosensors and Therapeutics. Advanced Healthcare Materials, 2021, 10, e2002205. | 3.9 | 51 |
| 464 | Stoichiometry of multi-specific immune checkpoint RNA Abs for TÂcell activation and tumor inhibition using ultra-stable RNA nanoparticles. Molecular Therapy - Nucleic Acids, 2021, 24, 426-435. | 2.3 | 5 |
| 465 | A Pilot Study of Whether the Cold-Heat Syndrome Type is Associated with Treatment Response and Immune Status in Patients with Non-Small Cell Lung Cancer. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11. | 0.5 | 3 |
| 466 | T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. British Journal of Cancer, 2021, 125, 717-724. | 2.9 | 12 |
| 467 | VISTA: A Promising Target for Cancer Immunotherapy?. ImmunoTargets and Therapy, 2021, Volume 10, 185-200. | 2.7 | 31 |
| 468 | Friends or Foes? An Update on Retinal Toxicities of Systemic Medications. Ophthalmic Surgery Lasers and Imaging Retina, 2021, 52, 302-306. | 0.4 | 0 |
| 469 | An immune-related model based on INHBA, JAG2 and CCL19 to predict the prognoses of colon cancer patients. Cancer Cell International, 2021, 21, 299. | 1.8 | 4 |
| 470 | Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. Future Oncology, 2021, 17, 2683-2692. | 1.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 471 | Cancer Immunotherapies: From Efficacy to Resistance Mechanisms â€“ Not Only Checkpoint Matters. Frontiers in Immunology, 2021, 12, 690112. | 2.2 | 42 |
| 472 | Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers, 2021, 13, 3415. | 1.7 | 15 |
| 473 | Perioperative clinical trials for glioma: Raising the bar. Journal of Clinical Neuroscience, 2021, 89, 144-150. | 0.8 | 5 |
| 474 | Severe Demyelinating Polyneuropathy and Cranial Neuropathy During Avelumab Treatment of Metastatic Merkel Cell Carcinoma. Clinical Neuropharmacology, 2021, 44, 193-195. | 0.2 | 4 |
| 475 | The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. Pharmaceutics, 2021, 13, 1016. | 2.0 | 9 |
| 476 | Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Russian Journal of Pediatric Hematology and Oncology, 2021, 8, 73-83. | 0.1 | 2 |
| 477 | Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 707198. | 1.8 | 17 |
| 478 | Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15. Cancer Immunology, Immunotherapy, 2021, 70, 2701-2719. | 2.0 | 8 |
| 479 | Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center. Cancer Research and Treatment, 2021, 53, 874-880. | 1.3 | 8 |
| 480 | Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma. Biology, 2021, 10, 674. | 1.3 | 4 |
| 481 | Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. Vaccines, 2021, 9, 807. | 2.1 | 2 |
| 482 | Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer, 2021, 21, 817. | 1.1 | 2 |
| 483 | Mechanisms involved in selecting and maintaining neuroblastoma cancer stem cell populations, and perspectives for therapeutic targeting. World Journal of Stem Cells, 2021, 13, 685-736. | 1.3 | 3 |
| 484 | Lytic Release of Cellular ATP: Physiological Relevance and Therapeutic Applications. Life, 2021, 11, 700. | 1.1 | 10 |
| 485 | Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infectionâ€”A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?. Cells, 2021, 10, 1817. | 1.8 | 8 |
| 486 | Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 678409. | 1.6 | 15 |
| 487 | Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma. Case Reports in Oncology, 2021, 14, 1051-1058. | 0.3 | 5 |
| 488 | Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. Microorganisms, 2021, 9, 1469. | 1.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 489 | Classification of Lung Adenocarcinoma Based on Immune Checkpoint and Screening of Related Genes. Journal of Oncology, 2021, 2021, 1-12. | 0.6 | 6 |
| 490 | Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports, 2021, 23, 98. | 1.3 | 34 |
| 491 | Predictive value of 3â€²-deoxy-3â€²-<sup>18</sup>F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. , 2021, 9, e003079. | | 5 |
| 492 | The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. International Journal of Molecular Sciences, 2021, 22, 8036. | 1.8 | 11 |
| 493 | Lysosomal nitric oxide determines transition from autophagy to ferroptosis after exposure to plasma-activated Ringer's lactate. Redox Biology, 2021, 43, 101989. | 3.9 | 55 |
| 494 | Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform. Nano Letters, 2021, 21, 6022-6030. | 4.5 | 25 |
| 495 | Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment. Frontiers in Oncology, 2021, 11, 720125. | 1.3 | 18 |
| 496 | Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. Frontiers in Immunology, 2021, 12, 592031. | 2.2 | 6 |
| 497 | Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Frontiers in Molecular Neuroscience, 2021, 14, 710171. | 1.4 | 6 |
| 498 | Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines, 2021, 9, 724. | 2.1 | 27 |
| 499 | The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy. Cancer Letters, 2021, 510, 67-78. | 3.2 | 60 |
| 500 | Heterogeneous Myeloid Cells in Tumors. Cancers, 2021, 13, 3772. | 1.7 | 30 |
| 501 | Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers. Cancers, 2021, 13, 3725. | 1.7 | 7 |
| 502 | A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumorâ€“Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy. Cancers, 2021, 13, 3751. | 1.7 | 18 |
| 503 | GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. , 2021, 9, e003005. | | 22 |
| 504 | GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer. Frontiers in Immunology, 2021, 12, 660397. | 2.2 | 13 |
| 505 | Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update. Brain Sciences, 2021, 11, 1035. | 1.1 | 6 |
| 506 | Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8â€‰+â€‰T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1119-1129. | 1.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 507 | Immune checkpoint inhibitorâ€“associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. European Journal of Cancer, 2021, 158, 208-216. | 1.3 | 33 |
| 508 | Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma. Polymers, 2021, 13, 2726. | 2.0 | 6 |
| 509 | CD47-SIRPÎ± Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. Cancers, 2021, 13, 4261. | 1.7 | 15 |
| 510 | Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis. Immunotherapy, 2021, 13, 1271-1282. | 1.0 | 13 |
| 511 | Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy. Seminars in Cancer Biology, 2022, 86, 1066-1075. | 4.3 | 14 |
| 512 | Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Frontiers in Pharmacology, 2021, 12, 720692. | 1.6 | 20 |
| 513 | Siglecâ€15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44. FEBS Letters, 2021, 595, 2290-2302. | 1.3 | 16 |
| 514 | Photodynamic Therapy for the Treatment and Diagnosis of Cancerâ€“A Review of the Current Clinical Status. Frontiers in Chemistry, 2021, 9, 686303. | 1.8 | 172 |
| 515 | Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors. Cureus, 2021, 13, e16829. | 0.2 | 7 |
| 516 | Enhanced CXCR4 Expression of Human CD8Low T Lymphocytes Is Driven by S1P4. Frontiers in Immunology, 2021, 12, 668884. | 2.2 | 8 |
| 517 | Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. Frontiers in Cell and Developmental Biology, 2021, 9, 701429. | 1.8 | 16 |
| 518 | Sex Differences in Cancer Genomes: Much Learned, More Unknown. Endocrinology, 2021, 162, . | 1.4 | 5 |
| 519 | Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. ACS Synthetic Biology, 2021, 10, 2087-2095. | 1.9 | 14 |
| 520 | Clinical Perspectives of Single-Cell RNA Sequencing. Biomolecules, 2021, 11, 1161. | 1.8 | 11 |
| 521 | Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma. Chinese Medical Journal, 2021, 134, 2066-2072. | 0.9 | 6 |
| 522 | PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. Immunotherapy, 2021, 13, 1053-1065. | 1.0 | 16 |
| 523 | Engineering stromal heterogeneity in cancer. Advanced Drug Delivery Reviews, 2021, 175, 113817. | 6.6 | 7 |
| 524 | Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 695325. | 1.8 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 525 | Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a metaâ€analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1122-1135. | 2.9 | 47 |
| 526 | Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Immunology, Immunotherapy, 2022, 71, 851-863. | 2.0 | 6 |
| 527 | Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 651634. | 2.2 | 47 |
| 528 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer, 2022, 25, 207-217. | 2.7 | 9 |
| 529 | Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy. Rheumatology and Therapy, 2021, 8, 1651-1659. | 1.1 | 1 |
| 530 | ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. Frontiers in Genetics, 2021, 12, 723670. | 1.1 | 9 |
| 531 | Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. Biomaterials, 2021, 276, 121058. | 5.7 | 13 |
| 532 | Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types. Journal of Molecular Diagnostics, 2021, 23, 1159-1173. | 1.2 | 7 |
| 533 | Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. Biomedicines, 2021, 9, 1277. | 1.4 | 38 |
| 534 | Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 730320. | 2.2 | 39 |
| 535 | An Integrative Pan-Cancer Analysis of the Prognostic and Immunological Role of Casein Kinase 2 Alpha Protein 1 (CSNK2A1) in Human Cancers: AStudy Based on Bioinformatics and Immunohistochemical Analysis. International Journal of General Medicine, 2021, Volume 14, 6215-6232. | 0.8 | 5 |
| 536 | Immune PET Imaging. Radiologic Clinics of North America, 2021, 59, 875-886. | 0.9 | 2 |
| 537 | CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene, 2021, 40, 6223-6234. | 2.6 | 42 |
| 538 | Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Research Europe, 0, 1, 107. | 2.0 | 1 |
| 539 | Identification of Prognostic Metabolism-Related Genes in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2021, 2021, 1-13. | 0.6 | 9 |
| 540 | Cardiac MRI Depicts Immune Checkpoint Inhibitorâ€“induced Myocarditis: A Prospective Study. Radiology, 2021, 301, 602-609. | 3.6 | 22 |
| 541 | Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 10009. | 1.8 | 14 |
| 542 | The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 543 | Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor. Cell Chemical Biology, 2021, 28, 1258-1270.e13. | 2.5 | 21 |
| 544 | Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients. Biomolecules, 2021, 11, 1425. | 1.8 | 12 |
| 545 | PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends in Molecular Medicine, 2021, 27, 868-881. | 3.5 | 30 |
| 546 | Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunological Investigations, 2022, 51, 1498-1514. | 1.0 | 8 |
| 547 | Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. Seminars in Cancer Biology, 2021, 74, 24-44. | 4.3 | 34 |
| 548 | Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. International Immunopharmacology, 2021, 98, 107876. | 1.7 | 15 |
| 549 | AXTEX-4D: A Three-DimensionalEx VivoPlatform for Preclinical Investigations of Immunotherapy Agents. Assay and Drug Development Technologies, 2021, 19, 361-372. | 0.6 | 3 |
| 550 | The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. Computational and Structural Biotechnology Journal, 2021, 19, 5428-5442. | 1.9 | 5 |
| 551 | MSI testing. Der Pathologe, 2021, 42, 110-118. | 0.7 | 9 |
| 552 | Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by TÂcell responses. Molecular Therapy - Oncolytics, 2021, 22, 399-409. | 2.0 | 2 |
| 553 | Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol. BMJ Open, 2021, 11, e048141. | 0.8 | 2 |
| 554 | A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open, 2021, 6, 100272. | 2.0 | 34 |
| 555 | Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer. Life Sciences, 2021, 282, 119848. | 2.0 | 8 |
| 556 | A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 434-446. | 0.9 | 16 |
| 557 | Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). Journal of Medicinal Chemistry, 2021, 64, 14757-14772. | 2.9 | 13 |
| 558 | Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A caseâ€“control study. European Journal of Cancer, 2021, 156, 46-59. | 1.3 | 16 |
| 559 | Avoiding immunogenic drugs is key to preserve renal function in patients receiving immune checkpoint inhibitors: Lessons learned from three illustrative cases. Journal of Onco-Nephrology, 0, , 239936932110485. | 0.3 | 1 |
| 560 | Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. International Immunopharmacology, 2021, 99, 107935. | 1.7 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 561 | Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. European Journal of Pharmacology, 2021, 909, 174404. | 1.7 | 18 |
| 562 | Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay. Journal of Immunological Methods, 2021, 498, 113134. | 0.6 | 1 |
| 563 | New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188624. | 3.3 | 29 |
| 564 | Discovery of 4-aminoquinolines as highly selective TGFÎ²R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. European Journal of Medicinal Chemistry, 2021, 225, 113763. | 2.6 | 1 |
| 565 | Immune checkpoint inhibitors: An emergency medicine focused review. American Journal of Emergency Medicine, 2021, 50, 335-344. | 0.7 | 5 |
| 566 | Management of Advanced Disease in NSCLC. , 2022, , 912-920. | | 0 |
| 567 | Targeted photodynamic immunotherapy. , 2022, , 463-481. | | 1 |
| 568 | Stromal modulation strategies to improve immunotherapy response in cancer. , 2022, , 241-291. | | 0 |
| 569 | Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497. | | 0 |
| 570 | Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner. Gene, 2022, 808, 145966. | 1.0 | 1 |
| 571 | Delivery strategies for immune checkpoint blockade. , 2022, , 1-29. | | 0 |
| 572 | Polymeric scaffolds for antitumor immune cell priming. , 2022, , 63-95. | | 2 |
| 573 | Impact of immune checkpoint gene CD155 Ala67Thr and CD226 Gly307Ser polymorphisms on small cell lung cancer clinical outcome. Scientific Reports, 2021, 11, 1794. | 1.6 | 3 |
| 574 | Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy. Cancers, 2021, 13, 288. | 1.7 | 12 |
| 575 | Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma. Functional and Integrative Genomics, 2021, 21, 125-138. | 1.4 | 5 |
| 576 | A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics, 2021, 11, 6936-6949. | 4.6 | 16 |
| 577 | The effect of PEGylation on the efficacy and uptake of an immunostimulatory nanoparticle in the tumor immune microenvironment. Nanoscale Advances, 2021, 3, 4961-4972. | 2.2 | 15 |
| 578 | Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. Chemical Communications, 2021, 57, 367-370. | 2.2 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 579 | Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies, 2021, 20, 153473542199007. | 0.8 | 25 |
| 580 | Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro. Gut Microbes, 2021, 13, 1-20. | 4.3 | 9 |
| 581 | Germline Genetics in Cancer: The New Frontier. , 2021, , 379-385. | | 0 |
| 582 | Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, . | 0.2 | 8 |
| 583 | Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines, 2021, 9, 64. | 2.1 | 11 |
| 584 | Structureâ€“Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists. Journal of Medicinal Chemistry, 2021, 64, 1649-1669. | 2.9 | 21 |
| 585 | Cancerâ€onâ€aâ€Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions. Small, 2021, 17, e2004282. | 5.2 | 30 |
| 586 | TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. Journal of Leukocyte Biology, 2020, 107, 981-991. | 1.5 | 22 |
| 587 | Bioinformatics for Cancer Immunotherapy. Methods in Molecular Biology, 2020, 2120, 1-9. | 0.4 | 22 |
| 588 | CCL22 Signaling in the Tumor Environment. Advances in Experimental Medicine and Biology, 2020, 1231, 79-96. | 0.8 | 30 |
| 589 | CAR T Cell Therapy Progress and Challenges for Solid Tumors. Cancer Treatment and Research, 2020, 180, 297-326. | 0.2 | 23 |
| 590 | The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. Gynecologic Oncology, 2020, 158, 167-177. | 0.6 | 20 |
| 591 | Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene, 2020, 39, 2835-2843. | 2.6 | 15 |
| 592 | Translational approaches to treating dynamical diseases through in silico clinical trials. Chaos, 2020, 30, 123128. | 1.0 | 21 |
| 593 | Photothermal therapies to improve immune checkpoint blockade for cancer. International Journal of Hyperthermia, 2020, 37, 34-49. | 1.1 | 23 |
| 594 | The current landscape of single-cell transcriptomics for cancer immunotherapy. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 35 |
| 595 | Innovations in targeted therapies for triple negative breast cancer. Current Opinion in Obstetrics and Gynecology, 2021, 33, 34-47. | 0.9 | 4 |
| 596 | Operative Trauma and Blood Loss â€" Impact on Tumor Growth and Recurrence. Shock, 2021, 55, 455-464. | 1.0 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 597 | Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1). Acta Crystallographica Section F, Structural Biology Communications, 2021, 77, 22-28. | 0.4 | 6 |
| 598 | Systematic review with metaâ€analysis: safety and tolerability of immune checkpoint inhibitors in patients with preâ€existing inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2021, 53, 374-382. | 1.9 | 54 |
| 599 | Targeting DNA binding proteins for cancer therapy. Cancer Science, 2020, 111, 1058-1064. | 1.7 | 17 |
| 600 | Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model. , 2020, 8, e001513. | | 17 |
| 601 | Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. , 2020, 8, e001532. | | 38 |
| 602 | Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight, 2020, 5, . | 2.3 | 11 |
| 603 | Cancer immunotherapy needs to learn how to stick to its guns. Journal of Clinical Investigation, 2019, 129, 5089-5091. | 3.9 | 2 |
| 604 | BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precision Oncology, 2020, 4, 1393-1402. | 1.5 | 52 |
| 605 | New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological, and cellular therapies. F1000Research, 2019, 8, 1202. | 0.8 | 3 |
| 606 | Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. Gastroenterology Research, 2020, 13, 227-232. | 0.4 | 7 |
| 607 | Suicide among cancer patients: adolescents and young adult (AYA) versus all-age patients. Annals of Translational Medicine, 2019, 7, 658-658. | 0.7 | 14 |
| 608 | Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414. | 0.9 | 10 |
| 609 | Current Progresses of Functional Nanomaterials for Imaging Diagnosis and Treatment of Melanoma. Current Topics in Medicinal Chemistry, 2019, 19, 2494-2506. | 1.0 | 6 |
| 610 | Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185. | 0.4 | 8 |
| 611 | Oncolytic virotherapy: new weapon for breast cancer treatment. Ecancermedicalscience, 2020, 14, 1149. | 0.6 | 12 |
| 612 | Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma. Frontiers in Veterinary Science, 2021, 8, 621758. | 0.9 | 6 |
| 613 | Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17. | 1.2 | 14 |
| 614 | The Proteomic Landscape of Resting and Activated CD4+ T Cells Reveal Insights into Cell Differentiation and Function. International Journal of Molecular Sciences, 2021, 22, 275. | 1.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 615 | Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review). International Journal of Molecular Medicine, 2020, 47, 444-454. | 1.8 | 16 |
| 616 | Immune-checkpoint inhibitors from cancer to COVIDâ€'19: A promising avenue for the treatment of patients with COVIDâ€'19 (Review). International Journal of Oncology, 2020, 58, 145-157. | 1.4 | 55 |
| 617 | Prognostic value of immune cell infiltration in bladder cancer: A gene expressionâ€'based study. Oncology Letters, 2020, 20, 1677-1684. | 0.8 | 6 |
| 618 | Interferonâ€'Î³ induced PDâ€'L1 expression and soluble PDâ€'L1 production in gastric cancer. Oncology Letters, 2020, 20, 2161-2168. | 0.8 | 28 |
| 619 | Early response of bone metastases can predict tumor response in patients with nonâ€'smallâ€'cell lung cancer with bone metastases in the treatment with nivolumab. Oncology Letters, 2020, 20, 2977-2986. | 0.8 | 11 |
| 620 | Immune checkpoint inhibitors in the driverâ€™s seat: Evaluating the evolving evidence in the treatment of extensive-stage small-cell lung cancer. Journal of Current Oncology, 2019, 2, 43. | 0.2 | 1 |
| 621 | Molecular modulation of autophagy: New venture to target resistant cancer stem cells. World Journal of Stem Cells, 2020, 12, 303-322. | 1.3 | 19 |
| 622 | Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 700-708. | 2.3 | 19 |
| 623 | Sex-Based Differences in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1329, 499-533. | 0.8 | 3 |
| 624 | Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology, 2022, 3, 140-169. | 2.0 | 5 |
| 625 | Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 53-63. | 2.3 | 6 |
| 626 | Molecular Signature Expands the Landscape of Driver Negative Thyroid Cancers. Cancers, 2021, 13, 5184. | 1.7 | 0 |
| 627 | Vaccines for Non-Viral Cancer Prevention. International Journal of Molecular Sciences, 2021, 22, 10900. | 1.8 | 4 |
| 628 | Development and Verification of an Autophagy-Related lncRNA Signature to Predict Clinical Outcomes and Therapeutic Responses in Ovarian Cancer. Frontiers in Medicine, 2021, 8, 715250. | 1.2 | 8 |
| 629 | Nanoparticle-Mediated In Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy. ACS Nano, 2021, 15, 17549-17564. | 7.3 | 16 |
| 630 | Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment. BMC Cancer, 2021, 21, 1134. | 1.1 | 7 |
| 631 | The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review. Frontiers in Pharmacology, 2021, 12, 737674. | 1.6 | 7 |
| 632 | MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer. Current Issues in Molecular Biology, 2021, 43, 1529-1547. | 1.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 633 | A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis. Epileptic Disorders, 2021, 23, 733-738. | 0.7 | 1 |
| 634 | Supramolecular peptide nanostructures: Self-assembly and biomedical applications. Giant, 2022, 9, 100082. | 2.5 | 15 |
| 635 | Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs. Frontiers in Molecular Biosciences, 2021, 8, 715764. | 1.6 | 4 |
| 636 | Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers, 2021, 13, 5049. | 1.7 | 2 |
| 637 | PDâ^'L1 immunostaining: what pathologists need to know. Diagnostic Pathology, 2021, 16, 94. | 0.9 | 39 |
| 638 | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report. Frontiers in Medicine, 2021, 8, 742489. | 1.2 | 2 |
| 639 | Antiâ€"PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells. Clinical Cancer Research, 2022, 28, 215-226. | 3.2 | 5 |
| 640 | Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Molecular Biology Reports, 2021, 48, 8075-8095. | 1.0 | 40 |
| 641 | Construction of a Ferroptosis-Related Gene Signature for Predicting Survival and Immune Microenvironment in Melanoma Patients. International Journal of General Medicine, 2021, Volume 14, 6423-6438. | 0.8 | 15 |
| 642 | Immunological and prognostic significance of CBX2 expression in hepatocellular carcinoma. World Chinese Journal of Digestology, 2021, 29, 1118-1129. | 0.0 | 0 |
| 643 | Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 721181. | 1.6 | 5 |
| 644 | Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Molecular Cancer, 2021, 20, 131. | 7.9 | 702 |
| 645 | A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody. Immunology Letters, 2021, 240, 137-148. | 1.1 | 4 |
| 646 | Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis. International Immunopharmacology, 2021, 101, 108242. | 1.7 | 5 |
| 651 | Immunotherapy of Gastric and Esophageal Cancers. , 2020, , 213-240. | | 0 |
| 652 | Gene expression in peripheral blood cells for differentiation of active and latent tuberculosis infection in children and adolescents. Tuberculosis and Lung Diseases, 2020, 97, 28-32. | 0.2 | 0 |
| 654 | Preclinical imaging for targeting cancer immune evasion. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 186-193. | 0.4 | 1 |
| 655 | A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. Cureus, 2020, 12, e8093. | 0.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 656 | Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma. PeerJ, 2020, 8, e9362. | 0.9 | 3 |
| 657 | Using the TCGA Database to Predict and Analyze Tumor Microenvironment Genes Related to Poor Prognosis of Colon Cancer. Medical Science Monitor, 2020, 26, e923707. | 0.5 | 2 |
| 658 | RANBP9 as potential therapeutic target in non-small cell lung cancer. Journal of Cancer Metastasis and Treatment, 2020, 2020, . | 0.5 | 1 |
| 659 | Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control. Open Research Europe, 0, 1, 107. | 2.0 | 1 |
| 660 | Nivolumab-Induced Crescentic Immunoglobulin A Nephropathy With Henoch-Schonlein Purpura Features in a Patient Diagnosed With Hepatocellular Carcinoma. Cureus, 2021, 13, e19110. | 0.2 | 1 |
| 661 | Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. Kidney Cancer, 2021, 5, 167-179. | 0.2 | 1 |
| 662 | Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer: Targets and Therapy, 2021, Volume 12, 123-131. | 1.3 | 4 |
| 663 | Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncology, 2021, 123, 105587. | 0.8 | 2 |
| 665 | Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. Methods in Molecular Biology, 2020, 2184, 233-263. | 0.4 | 1 |
| 666 | Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma. Minerva Medica, 2020, 111, 589-600. | 0.3 | 0 |
| 667 | An Integrative Analysis Reveals the Potential Mechanism between Herbal Medicine Yinchen and Immunoregulation in Hepatocellular Carcinoma. BioMed Research International, 2020, 2020, 1-10. | 0.9 | 6 |
| 668 | Immune Cell Therapy Against Gastrointestinal Tract Cancers. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 61-77. | 0.2 | 0 |
| 669 | BET mechanisms in cancer. , 2020, , 101-142. | | 0 |
| 670 | Therapeutic Vaccines for Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 113-158. | 0.2 | 1 |
| 671 | Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Drug Delivery, 2021, 28, 2313-2328. | 2.5 | 5 |
| 672 | Immune Modulating Antibodyâ€“Drug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726. | 2.9 | 35 |
| 673 | Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts. Frontiers in Chemistry, 2021, 9, 766107. | 1.8 | 7 |
| 674 | Context Mattersâ€”Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 760705. | 1.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 676 | Clinical significance of herpes virus entry mediator expression in hepatitis B virusâ€'related hepatocellular carcinoma. Oncology Letters, 2020, 20, 19. | 0.8 | 8 |
| 678 | Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. Oncotarget, 2020, 11, 3972-3983. | 0.8 | 2 |
| 680 | CD122-targeted interleukin-2 and Î±PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. OncoImmunology, 2021, 10, 2006529. | 2.1 | 1 |
| 681 | Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. Cancer Treatment and Research Communications, 2021, 29, 100489. | 0.7 | 2 |
| 682 | Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation. , 2021, , 277-304. | | 0 |
| 683 | Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 751209. | 1.3 | 10 |
| 684 | HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy. Scientific Reports, 2021, 11, 22158. | 1.6 | 6 |
| 685 | Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases. Frontiers in Genetics, 2021, 12, 785153. | 1.1 | 28 |
| 686 | Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives. Cancers, 2021, 13, 5999. | 1.7 | 6 |
| 687 | Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 762478. | 1.8 | 8 |
| 688 | Anticancer natural products targeting immune checkpoint protein network. Seminars in Cancer Biology, 2022, 86, 1008-1032. | 4.3 | 8 |
| 689 | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Communication and Signaling, 2021, 19, 117. | 2.7 | 25 |
| 690 | Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression. Acta Neuropathologica Communications, 2021, 9, 183. | 2.4 | 21 |
| 691 | Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 785185. | 1.1 | 13 |
| 692 | A Novel Nine-Gene Signature Associated With Immune Infiltration for Predicting Prognosis in Hepatocellular Carcinoma. Frontiers in Genetics, 2021, 12, 730732. | 1.1 | 2 |
| 693 | C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models. Cancer Immunology Research, 2022, 10, 245-258. | 1.6 | 7 |
| 694 | Penpulimab: First Approval. Drugs, 2021, 81, 2159-2166. | 4.9 | 17 |
| 695 | Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1725-1740. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 696 | The clinical utility and safety of shortâ€course immune checkpoint inhibitors in multiple tumoursâ€"A realâ€world multicentric study from India. International Journal of Cancer, 2021, , . | 2.3 | 5 |
| 697 | KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11. | 1.3 | 4 |
| 698 | Sarcopeniaâ€™s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 5329. | 1.0 | 8 |
| 699 | A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma. Aging, 2021, 13, 24866-24881. | 1.4 | 4 |
| 700 | Impact of immune cells on the hallmarks of cancer: A literature review. Critical Reviews in Oncology/Hematology, 2021, 168, 103541. | 2.0 | 27 |
| 701 | Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. International Immunopharmacology, 2021, 101, 108337. | 1.7 | 3 |
| 702 | Genetic Association and Mendelian Randomization for Hypothyroidism Highlight Immune Molecular Mechanisms. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 703 | External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , . | | 0 |
| 704 | Comprehensive genomic profiling and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the stomach and parotid gland. Annals of Translational Medicine, 2022, 10, 13-13. | 0.7 | 0 |
| 705 | Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade. OncoImmunology, 2021, 10, . | 2.1 | 14 |
| 706 | Immunotherapy in skin cancers - A narrative review. Journal of Skin and Sexually Transmitted Diseases, 0, . | 0.0 | 0 |
| 707 | Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers, 2022, 14, 294. | 1.7 | 24 |
| 708 | Cancer immunomodulation using bispecific aptamers. Molecular Therapy - Nucleic Acids, 2022, 27, 894-915. | 2.3 | 20 |
| 709 | Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. Biomedicine and Pharmacotherapy, 2022, 146, 112558. | 2.5 | 10 |
| 710 | BACH1 as a potential target for immunotherapy in glioblastomas. International Immunopharmacology, 2022, 103, 108451. | 1.7 | 11 |
| 711 | The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomedicine and Pharmacotherapy, 2022, 146, 112516. | 2.5 | 38 |
| 712 | PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology, 2022, 103, 108484. | 1.7 | 2 |
| 713 | Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool. JPRAS Open, 2022, 31, 114-122. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 714 | Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features. Journal of Nippon Medical School, 2022, 89, 128-138. | 0.3 | 4 |
| 715 | Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022, 11, 320. | 1.8 | 43 |
| 716 | Eosinophils and melanoma: Implications for immunotherapy. Pigment Cell and Melanoma Research, 2022, 35, 192-202. | 1.5 | 5 |
| 717 | Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients. Frontiers in Immunology, 2021, 12, 797407. | 2.2 | 9 |
| 718 | Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 1455-1466. | 1.5 | 7 |
| 719 | XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 16 |
| 720 | Cell Communication Network factor 4 promotes tumorâ€induced immunosuppression in melanoma. EMBO Reports, 2022, 23, e54127. | 2.0 | 6 |
| 721 | Construction of Molecular Subtypes and Related Prognostic and Immune Response Models Based on M2 Macrophages in Glioblastoma. International Journal of General Medicine, 2022, Volume 15, 913-926. | 0.8 | 2 |
| 722 | Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 806963. | 1.3 | 14 |
| 723 | Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 2022, 22, 2. | 1.8 | 83 |
| 724 | The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer. Experimental and Molecular Medicine, 2022, 54, 12-22. | 3.2 | 12 |
| 725 | Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence. Cancers, 2022, 14, 213. | 1.7 | 0 |
| 726 | mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 727 | Systematic analysis of the role of SLC52A2 in multiple human cancers. Cancer Cell International, 2022, 22, 8. | 1.8 | 7 |
| 728 | Emerging strategies for biomaterial-assisted cancer immunotherapy. Korean Journal of Chemical Engineering, 2022, 39, 227-240. | 1.2 | 1 |
| 729 | Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 2022, 28, 368-377. | 3.2 | 40 |
| 730 | Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy. Nanotheranostics, 2022, 6, 243-255. | 2.7 | 17 |
| 731 | Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma. PeerJ, 2022, 10, e12646. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 733 | Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy's existing prospects and challenges in drug targets. Current Drug Targets, 2022, 23, . | 1.0 | 2 |
| 734 | Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice. Hepatology, 2022, 76, 630-645. | 3.6 | 13 |
| 735 | Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma. International Journal of General Medicine, 2022, Volume 15, 437-449. | 0.8 | 2 |
| 736 | Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review). International Journal of Oncology, 2022, 60, . | 1.4 | 7 |
| 737 | PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers. Biomedicines, 2022, 10, 299. | 1.4 | 3 |
| 738 | Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Molecular Cancer, 2022, 21, 31. | 7.9 | 42 |
| 739 | The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes. Asia-Pacific Journal of Clinical Oncology, 2022, , . | 0.7 | 2 |
| 740 | Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-11. | 1.9 | 14 |
| 741 | The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. Frontiers in Immunology, 2022, 13, 811200. | 2.2 | 7 |
| 742 | The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Critical Reviews in Oncology/Hematology, 2022, 170, 103596. | 2.0 | 76 |
| 743 | Bilateral diffuse uveal melanocytic proliferation: Report of a novel optical coherence tomography finding and clinical response to plasmapheresis. American Journal of Ophthalmology Case Reports, 2022, 25, 101349. | 0.4 | 3 |
| 744 | The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111. | | 25 |
| 745 | The Efficacy and Safety of PD-1/PD-L1 Immunosuppressive Agents in Advanced Esophageal Cancer: A Meta-Analysis. Advances in Clinical Medicine, 2022, 12, 828-837. | 0.0 | 0 |
| 746 | Antibodyâ€incorporated Nanomedicines for Cancer Therapy. Advanced Materials, 2022, 34, e2109210. | 11.1 | 32 |
| 747 | Neutrophilâ€toâ€lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Metaâ€analysis. Head and Neck, 2022, 44, 1237-1245. | 0.9 | 20 |
| 748 | Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Seminars in Cancer Biology, 2022, 86, 542-565. | 4.3 | 51 |
| 749 | Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials. ESMO Open, 2022, 7, 100396. | 2.0 | 9 |
| 750 | Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis. Frontiers in Genetics, 2022, 13, 820135. | 1.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 751 | Immunotherapies for hepatocellular carcinoma. Cancer Medicine, 2022, 11, 571-591. | 1.3 | 29 |
| 752 | ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. Journal of Cancer, 2022, 13, 1933-1944. | 1.2 | 6 |
| 753 | The role of DNA mismatch repair in immunotherapy of human cancer. International Journal of Biological Sciences, 2022, 18, 2821-2832. | 2.6 | 20 |
| 754 | Modelâ€informed drug development supporting the approval of the avelumab flatâ€dose regimen in patients with advanced renal cell carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 458-468. | 1.3 | 5 |
| 755 | PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and Î²-catenin signaling pathways. Scientific Reports, 2022, 12, 3053. | 1.6 | 23 |
| 756 | RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. Journal of Experimental and Clinical Cancer Research, 2022, 41, 66. | 3.5 | 18 |
| 757 | New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. Cells, 2022, 11, 768. | 1.8 | 14 |
| 758 | Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines, 2022, 10, 537. | 1.4 | 9 |
| 759 | An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets. Life, 2022, 12, 323. | 1.1 | 4 |
| 760 | Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma. Scientific Reports, 2022, 12, 3079. | 1.6 | 6 |
| 761 | Histone Deacetylases as Modulators of the Crosstalk Between Skeletal Muscle and Other Organs. Frontiers in Physiology, 2022, 13, 706003. | 1.3 | 8 |
| 762 | CD84 is a Suppressor of T and B Cell Activation during Mycobacterium tuberculosis Pathogenesis. Microbiology Spectrum, 2022, 10, e0155721. | 1.2 | 3 |
| 763 | Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications. Cancer Gene Therapy, 2022, 29, 1307-1320. | 2.2 | 4 |
| 764 | Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. Seminars in Cancer Biology, 2022, 86, 909-922. | 4.3 | 26 |
| 765 | Genome-wide identification and analysis of prognostic features in human cancers. Cell Reports, 2022, 38, 110569. | 2.9 | 48 |
| 766 | Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. American Journal of Hematology, 2022, , . | 2.0 | 2 |
| 767 | TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. Frontiers in Immunology, 2022, 13, 832230. | 2.2 | 13 |
| 768 | Comprehensive Analysis Identified Mutation-Gene Signature Impacts the Prognosis Through Immune Function in Hepatocellular Carcinoma. Frontiers in Oncology, 2022, 12, 748557. | 1.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 769 | Recent advances in overcoming barriers to cellâ€based delivery systems for cancer immunotherapy. Exploration, 2022, 2, . | 5.4 | 68 |
| 770 | Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. Clinical and Experimental Immunology, 2022, 209, 64-71. | 1.1 | 5 |
| 771 | Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy. Cancer Biology and Therapy, 2022, 23, 104-111. | 1.5 | 19 |
| 772 | Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach. Journal of Clinical Medicine, 2022, 11, 1659. | 1.0 | 2 |
| 773 | Comprehensive Analysis of the Immune and Prognostic Implication of TRIM8 in Breast Cancer. Frontiers in Genetics, 2022, 13, 835540. | 1.1 | 1 |
| 774 | CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. Clinical and Experimental Immunology, 2022, 208, 220-232. | 1.1 | 6 |
| 775 | Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Seminars in Cancer Biology, 2022, 86, 137-150. | 4.3 | 70 |
| 776 | Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316. | | 45 |
| 777 | Identification and Verification of the Ferroptosis- and Pyroptosis-Associated Prognostic Signature for low-grade Glioma. Bosnian Journal of Basic Medical Sciences, 2022, , . | 0.6 | 14 |
| 778 | Recent advancements in lipidâ€“mRNA nanoparticles as a treatment option for cancer immunotherapy. Journal of Pharmaceutical Investigation, 2022, 52, 415-426. | 2.7 | 21 |
| 779 | Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine. Molecular Therapy - Oncolytics, 2022, 24, 650-662. | 2.0 | 2 |
| 780 | Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. Journal of Clinical Pharmacology, 2022, 62, 1059-1078. | 1.0 | 0 |
| 781 | Targeting CAFs to overcome anticancer therapeutic resistance. Trends in Cancer, 2022, 8, 527-555. | 3.8 | 68 |
| 782 | Development and Validation of a Novel Survival Model for Cutaneous Melanoma Based on Necroptosis-Related Genes. Frontiers in Oncology, 2022, 12, 852803. | 1.3 | 10 |
| 783 | Development of Peptide-Based Vaccines for Cancer. Journal of Oncology, 2022, 2022, 1-17. | 0.6 | 32 |
| 784 | Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Molecular Biomedicine, 2022, 3, 8. | 1.7 | 38 |
| 785 | Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data. Frontiers in Oncology, 2022, 12, 824511. | 1.3 | 9 |
| 786 | Kanser immÃ¼noterapisinde gÃ¼ncel yaklaÅŸÄ±mlar ve immÃ¼noterapinin sÄ±nÄ±rlayÄ±cÄ± etkilerine genel bakÄ±ÅŸ. Turkish Journal of Clinics and Laboratory, 0, , . | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 787 | Evaluation of autoantibodies as predictors of treatment response and immuneâ€related adverse events during the treatment with immune checkpoint inhibitors: AÂprospective longitudinal panâ€cancer study. Cancer Medicine, 2022, 11, 3074-3083. | 1.3 | 16 |
| 788 | Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Communication and Signaling, 2022, 20, 49. | 2.7 | 71 |
| 789 | A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. BMC Cancer, 2022, 22, 365. | 1.1 | 11 |
| 790 | The Role of NcRNAs to Regulate Immune Checkpoints in Cancer. Frontiers in Immunology, 2022, 13, 853480. | 2.2 | 12 |
| 791 | Self-assembling peptides-based nano-cargos for targeted chemotherapy and immunotherapy of tumors: recent developments, challenges, and future perspectives. Drug Delivery, 2022, 29, 1184-1200. | 2.5 | 17 |
| 792 | Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models. Cancer Immunology, Immunotherapy, 2022, 71, 2691-2700. | 2.0 | 5 |
| 793 | Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling, 2022, 20, 44. | 2.7 | 109 |
| 794 | A case report of longitudinal extensive transverse myelitis: immunotherapy related adverse effect vs. COVID-19 related immunization complications. International Journal of Neuroscience, 2022, , 1-4. | 0.8 | 7 |
| 795 | Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. Clinical and Experimental Medicine, 2023, 23, 313-331. | 1.9 | 21 |
| 796 | Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report. Frontiers in Oncology, 2022, 12, 801924. | 1.3 | 1 |
| 797 | Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. Frontiers in Immunology, 2022, 13, 840207. | 2.2 | 7 |
| 798 | High Expression of CSF-1R Predicts Poor Prognosis and CSF-1Rhigh Tumor-Associated Macrophages Inhibit Anti-Tumor Immunity in Colon Adenocarcinoma. Frontiers in Oncology, 2022, 12, 850767. | 1.3 | 6 |
| 799 | Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities. International Journal of Biological Macromolecules, 2022, 207, 1022-1037. | 3.6 | 9 |
| 800 | QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to KeytrudaÂ®. European Journal of Pharmaceutical Sciences, 2022, 173, 106171. | 1.9 | 6 |
| 801 | Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity. Expert Opinion on Drug Safety, 2022, 21, 599-612. | 1.0 | 1 |
| 802 | Challenges of cancer immunotherapy and chemotherapy during the COVID-19 pandemic. Tumori, 2021, , 030089162110639. | 0.6 | 4 |
| 803 | Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials. Cancers, 2022, 14, 52. | 1.7 | 11 |
| 804 | Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors. Life, 2021, 11, 1400. | 1.1 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 805 | A Five Collagen-Related Gene Signature to Estimate the Prognosis and Immune Microenvironment in Clear Cell Renal Cell Cancer. Vaccines, 2021, 9, 1510. | 2.1 | 3 |
| 806 | Moving forward in the treatment of cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 1939-1955. | 0.8 | 4 |
| 807 | The DNA damage repair-related gene PKMYT1 is a potential biomarker in various malignancies. Translational Lung Cancer Research, 2021, 10, 4600-4616. | 1.3 | 5 |
| 808 | Targeting Aggressive Pituitary Adenomas at the Molecular Levelâ€"A Review. Journal of Clinical Medicine, 2022, 11, 124. | 1.0 | 9 |
| 809 | CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. Oncology Letters, 2021, 23, 51. | 0.8 | 9 |
| 810 | A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients. International Journal of General Medicine, 2021, Volume 14, 10467-10481. | 0.8 | 2 |
| 811 | Dissection of Immune Profiles in Microsatellite Stable and Low Microsatellite Instability Colon Adenocarcinoma by Multiomics Data Analysis. Journal of Oncology, 2022, 2022, 1-20. | 0.6 | 0 |
| 812 | PMEPA1 Serves as a Prognostic Biomarker and Correlates with Immune Infiltrates in Cervical Cancer. Journal of Immunology Research, 2022, 2022, 1-11. | 0.9 | 1 |
| 813 | Identification of a pyroptosis-related prognostic signature in breast cancer. BMC Cancer, 2022, 22, 429. | 1.1 | 17 |
| 814 | Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. Cancer Medicine, 2022, 11, 3886-3901. | 1.3 | 9 |
| 815 | Platycodon grandiflorum Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8+ T Cells in Local Tumor Microenvironment. Frontiers in Pharmacology, 2022, 13, 774440. | 1.6 | 5 |
| 816 | Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis. Frontiers in Oncology, 2022, 12, 882531. | 1.3 | 13 |
| 817 | The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. Investigational New Drugs, 2022, 40, 810-817. | 1.2 | 5 |
| 818 | Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death and Disease, 2022, 13, 378. | 2.7 | 37 |
| 836 | Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. EXCLI Journal, 2022, 21, 250-268. | 0.5 | 10 |
| 837 | Escherichia coli Mimetic Gold Nanorod-Mediated Photo- and Immunotherapy for Treating Cancer and Its Metastasis. ACS Nano, 2022, 16, 8472-8483. | 7.3 | 26 |
| 838 | The Challenging Management of Cancer: An Immunonephrologistâ€™s Perspective. Kidney and Blood Pressure Research, 2021, 46, 114-120. | 0.9 | 2 |
| 839 | Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).. Iranian Journal of Basic Medical Sciences, 2021, 24, 1264-1271. | 1.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 842 | Development of Cancer Immunotherapies. Cancer Treatment and Research, 2022, 183, 1-48. | 0.2 | 4 |
| 843 | Intestinal stents: Structure, functionalization and advanced engineering innovation. , 2022, 137, 212810. | | 4 |
| 844 | A Systematic Pan-Cancer Analysis of CASP3 as a Potential Target for Immunotherapy. Frontiers in Molecular Biosciences, 2022, 9, 776808. | 1.6 | 10 |
| 845 | CHSY3 can be a Poor Prognostic Biomarker and Mediates Immune Evasion in Stomach Adenocarcinoma. Frontiers in Genetics, 2022, 13, 876588. | 1.1 | 0 |
| 846 | Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy. World Journal of Oncology, 2022, 13, 49-52. | 0.6 | 8 |
| 847 | A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma. Journal of Immunology Research, 2022, 2022, 1-13. | 0.9 | 5 |
| 848 | A prognostic model for oral squamous cell carcinoma using 7 genes related to tumor mutational burden. BMC Oral Health, 2022, 22, 152. | 0.8 | 5 |
| 849 | Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123483119. | 3.3 | 0 |
| 850 | From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade. Frontiers in Oncology, 2022, 12, . | 1.3 | 0 |
| 851 | The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development. Advanced Drug Delivery Reviews, 2022, 186, 114316. | 6.6 | 17 |
| 852 | Clinical applications of plasma proteomics and peptidomics: Towards precision medicine. Proteomics - Clinical Applications, 2022, 16, e2100097. | 0.8 | 20 |
| 853 | Characterizing the landscape of cervical squamous cell carcinoma immune microenvironment by integrating the singleâ€cell transcriptomics and RNAâ€Seq. Immunity, Inflammation and Disease, 2022, 10, . | 1.3 | 4 |
| 854 | An Autoimmune Encephalitis Case Associated with Pembrolizumab Use. Journal of the Korean Neurological Association, 2022, 40, 137-140. | 0.0 | 0 |
| 855 | Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1278-1298. | 2.5 | 36 |
| 856 | Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors. Siberian Journal of Oncology, 2022, 21, 109-117. | 0.1 | 0 |
| 857 | Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3878-3891. | 3.3 | 3 |
| 860 | Update in TIGIT Immune-Checkpoint Role in Cancer. Frontiers in Oncology, 2022, 12, . | 1.3 | 19 |
| 861 | An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. Scientific Reports, 2022, 12, 8230. | 1.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 862 | Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape. Expert Opinion on Therapeutic Targets, 2022, 26, 405-425. | 1.5 | 3 |
| 863 | Epitope Mapping and Binding Assessment by Solid-State NMR Provide a Way for the Development of Biologics under the Quality by Design Paradigm. Journal of the American Chemical Society, 2022, 144, 10006-10016. | 6.6 | 9 |
| 864 | Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics. Analytical Chemistry, 2022, 94, 7970-7980. | 3.2 | 5 |
| 865 | Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 54-74. | 2.0 | 3 |
| 866 | Preliminary Assessment of Cardiotoxicity in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 867 | Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. Cancers, 2022, 14, 2590. | 1.7 | 17 |
| 868 | mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. Journal of Translational Medicine, 2022, 20, . | 1.8 | 9 |
| 869 | Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Cancers, 2022, 14, 2545. | 1.7 | 37 |
| 870 | Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Advanced Drug Delivery Reviews, 2022, 187, 114365. | 6.6 | 30 |
| 871 | Associations of different immune checkpoints-expressing CD4+ Treg/ T cell subsets with disease-free survival in colorectal cancer patients. BMC Cancer, 2022, 22, . | 1.1 | 7 |
| 872 | Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Frontiers of Medicine, 2022, 16, 307-321. | 1.5 | 6 |
| 873 | Profiling the Tumor-Infiltrating Lymphocytes in Gastric Cancer Reveals Its Implication in the Prognosis. Genes, 2022, 13, 1017. | 1.0 | 2 |
| 874 | Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC. Lung Cancer, 2022, , . | 0.9 | 5 |
| 875 | High-Dose Vitamin C for Cancer Therapy. Pharmaceuticals, 2022, 15, 711. | 1.7 | 23 |
| 876 | IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 877 | High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 878 | Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers. Cancers, 2022, 14, 3104. | 1.7 | 1 |
| 879 | Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer. International Journal of Molecular Sciences, 2022, 23, 6473. | 1.8 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 880 | High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines, 2022, 10, 1405. | 1.4 | 1 |
| 881 | The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 882 | The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and metaâ€analysis. International Journal of Cancer, 2022, 151, 1626-1639. | 2.3 | 8 |
| 883 | Emerging trends in immunotoxin targeting cancer stem cells. Toxicology in Vitro, 2022, 83, 105417. | 1.1 | 8 |
| 884 | Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Frontiers in Pharmacology, 0, 13, . | 1.6 | 134 |
| 885 | A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 886 | Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer. Journal of Personalized Medicine, 2022, 12, 1039. | 1.1 | 3 |
| 887 | Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 12 |
| 888 | A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment. Frontiers in Oncology, 0, 12, . | 1.3 | 7 |
| 889 | Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma. BMC Cancer, 2022, 22, . | 1.1 | 3 |
| 890 | Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 891 | Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 861-874. | 1.1 | 6 |
| 892 | Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 3440. | 1.7 | 1 |
| 893 | Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort. Discover Oncology, 2022, 13, . | 0.8 | 3 |
| 894 | Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, . | 2.4 | 5 |
| 895 | EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms. European Journal of Medical Research, 2022, 27, . | 0.9 | 6 |
| 896 | Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. Scientific Reports, 2022, 12, . | 1.6 | 2 |
| 897 | Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Frontiers in Nutrition, 0, 9, . | 1.6 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 898 | Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. Genes, 2022, 13, 1282. | 1.0 | 2 |
| 899 | Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system. Biomaterials, 2022, 288, 121677. | 5.7 | 4 |
| 900 | Extracellular Vesicles for Cancer Immunotherapy: Biomarkers and Beyond. Physiology, 0, , . | 4.0 | 0 |
| 901 | Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis. Vaccines, 2022, 10, 1195. | 2.1 | 11 |
| 902 | Glycometabolism-related gene signature of hepatocellular carcinoma predicts prognosis and guides immunotherapy. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 1 |
| 903 | Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity. Immunologic Research, 2022, 70, 725-741. | 1.3 | 13 |
| 904 | The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Frontiers in Immunology, 0, 13, . | 2.2 | 44 |
| 905 | Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Frontiers in Immunology, 0, 13, . | 2.2 | 20 |
| 906 | Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1Î² and PD-1 inhibition. Future Oncology, 2022, 18, 3085-3100. | 1.1 | 9 |
| 907 | Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine. Investigational New Drugs, 2022, 40, 1173-1184. | 1.2 | 6 |
| 908 | Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. Clinical and Translational Oncology, 2022, 24, 2255-2271. | 1.2 | 6 |
| 909 | Efficacy and Safety of Apatinib for the Treatment of Advanced or Recurrent Cervical Cancer: A Single-Arm Meta-Analysis Among Chinese Patients. Frontiers in Pharmacology, 0, 13, . | 1.6 | 1 |
| 910 | Low-Intensity Focused Ultrasound Produces Immune Response in Pancreatic Cancer. Ultrasound in Medicine and Biology, 2022, 48, 2344-2353. | 0.7 | 7 |
| 911 | Echocardiographic and Cardiac MRI Comparison of Longitudinal Strain and Strain Rate in Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Personalized Medicine, 2022, 12, 1332. | 1.1 | 1 |
| 912 | Genetic association and Mendelian randomization for hypothyroidism highlight immune molecular mechanisms. IScience, 2022, 25, 104992. | 1.9 | 7 |
| 913 | The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. Journal of Clinical Medicine, 2022, 11, 4523. | 1.0 | 7 |
| 915 | Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. Journal of Hematology and Oncology, 2022, 15, . | 6.9 | 89 |
| 916 | Microenvironment in Oral Potentially Malignant Disorders: Multi-Dimensional Characteristics and Mechanisms of Carcinogenesis. International Journal of Molecular Sciences, 2022, 23, 8940. | 1.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 917 | Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. Cancers, 2022, 14, 3779. | 1.7 | 18 |
| 918 | Construction of a prognostic risk model based on apoptosis-related genes to assess tumor immune microenvironment and predict prognosis in hepatocellular carcinoma. BMC Gastroenterology, 2022, 22, . | 0.8 | 3 |
| 919 | Molecular Diagnostics and Immunological Markers of Neurodegenerative Disorders. , 2022, , 125-142. | | 0 |
| 920 | The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 3830. | 1.7 | 5 |
| 921 | Nanoscale Zeolitic Imidazolate Framework (ZIF)â€“8 in Cancer Theranostics: Current Challenges and Prospects. Cancers, 2022, 14, 3935. | 1.7 | 28 |
| 922 | Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis. Medicina (Lithuania), 2022, 58, 1069. | 0.8 | 19 |
| 923 | Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. Frontiers in Immunology, 0, 13, . | 2.2 | 4 |
| 924 | Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. Journal of Translational Medicine, 2022, 20, . | 1.8 | 9 |
| 925 | The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. Disease Markers, 2022, 2022, 1-8. | 0.6 | 1 |
| 926 | The epiphany derived from T-cellâ€“inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |
| 927 | Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 6 |
| 928 | The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy. Cancers, 2022, 14, 3833. | 1.7 | 4 |
| 929 | Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 1 |
| 930 | SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer. Aging, 2022, 14, 6316-6337. | 1.4 | 6 |
| 931 | Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 3828. | 1.7 | 3 |
| 933 | Treatment of gastric carcinoma with lymphoid stroma by immunotherapy: A case report. World Journal of Clinical Cases, 2022, 10, 8962-8967. | 0.3 | 2 |
| 934 | Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128947. | 1.0 | 6 |
| 935 | Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma. Cancer Discovery, 2022, 12, 2820-2837. | 7.7 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 936 | Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 937 | Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. Pathology Research and Practice, 2022, 238, 154110. | 1.0 | 1 |
| 938 | Integrative pan-cancer analysis indicates the prognostic importance of long noncoding RNA SNHG17 in human cancers. Pathology Research and Practice, 2022, 238, 154140. | 1.0 | 3 |
| 939 | Landscape of exitrons in gastric cancer. EBioMedicine, 2022, 84, 104272. | 2.7 | 1 |
| 940 | Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Molecular Therapy - Oncolytics, 2022, 27, 3-13. | 2.0 | 14 |
| 941 | Discovery of 3,4-Dihydropyrimido[4,5- <i>d</i>]Pyrimidin-2(1 <i>H</i>)-One and 3,4-Dihydropyrido[2,3- <i>d</i>]Pyrimidin-2(1 <i>H</i>)-One Derivatives as Novel ENPP1 Inhibitors. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 942 | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Computational and Structural Biotechnology Journal, 2022, 20, 5150-5161. | 1.9 | 5 |
| 943 | Clinical Approaches in Targeting ROS-Induced Cancer. , 2022, , 2599-2614. | | 0 |
| 944 | PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer. Nanoscale, 2022, 14, 14014-14022. | 2.8 | 1 |
| 945 | Pulmonology (Lung). , 2022, , 275-299. | | 1 |
| 946 | Medical use of cell-penetrating peptides: how far have they come?. , 2022, , 235-254. | | 0 |
| 947 | Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study. Journal of Gastrointestinal Cancer, 0, , . | 0.6 | 2 |
| 948 | T-Cell Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous Cell Cancer. Cancers, 2022, 14, 4246. | 1.7 | 4 |
| 949 | <scp>COL3A1</scp>: Potential prognostic predictor for head and neck cancer based on immuneâ€microenvironment alternative splicing. Cancer Medicine, 2023, 12, 4882-4894. | 1.3 | 7 |
| 950 | Gut microbiota shed new light on the management of <scp>immuneâ€related</scp> adverse events. Thoracic Cancer, 2022, 13, 2681-2691. | 0.8 | 10 |
| 951 | Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker. Frontiers in Cell and Developmental Biology, 0, 10, . | 1.8 | 4 |
| 952 | Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma. Aging, 2022, 14, 6917-6935. | 1.4 | 4 |
| 953 | Boosting the Immune Responseâ€"Combining Local and Immune Therapy for Prostate Cancer Treatment. Cells, 2022, 11, 2793. | 1.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 954 | Increased risk of incident diabetes after therapy with immune checkpoint inhibitor compared with conventional chemotherapy: A longitudinal trajectory analysis using a tertiary care hospital database. Metabolism: Clinical and Experimental, 2023, 138, 155311. | 1.5 | 4 |
| 955 | Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma. Nature Communications, 2022, 13, . | 5.8 | 16 |
| 956 | Plasmid DNA for Therapeutic Applications in Cancer. Pharmaceutics, 2022, 14, 1861. | 2.0 | 13 |
| 957 | Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors. Frontiers in Immunology, 0, 13, . | 2.2 | 5 |
| 959 | The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy. BMC Cancer, 2022, 22, . | 1.1 | 0 |
| 960 | Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer. Frontiers in Oncology, 0, 12, . | 1.3 | 14 |
| 961 | The pro-tumorigenic responses in metastatic niches: an immunological perspective. Clinical and Translational Oncology, 2023, 25, 333-344. | 1.2 | 3 |
| 963 | Artificial Intelligence-Powered Whole-Slide Image Analyzer Reveals a Distinctive Distribution of Tumor-Infiltrating Lymphocytes in Neuroendocrine Neoplasms. Diagnostics, 2022, 12, 2340. | 1.3 | 3 |
| 964 | Machine learning identification of cuproptosis and necroptosis-associated molecular subtypes to aid in prognosis assessment and immunotherapy response prediction in low-grade glioma. Frontiers in Genetics, 0, 13, . | 1.1 | 20 |
| 965 | In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. Nature Communications, 2022, 13, . | 5.8 | 15 |
| 967 | Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression. Angiogenesis, 0, , . | 3.7 | 2 |
| 968 | Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 969 | Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer. Combinatorial Chemistry and High Throughput Screening, 2022, 25, . | 0.6 | 1 |
| 970 | S-acylthioalkyl ester (SATE)-based prodrugs of deoxyribose cyclic dinucleotides (dCDNs) as the STING agonist for antitumor immunotherapy. European Journal of Medicinal Chemistry, 2022, 243, 114796. | 2.6 | 11 |
| 971 | The development of small-molecule inhibitors targeting HPK1. European Journal of Medicinal Chemistry, 2022, 244, 114819. | 2.6 | 12 |
| 972 | AKT Isoforms as a Target in Cancer and Immunotherapy. Current Topics in Microbiology and Immunology, 2022, , 409-436. | 0.7 | 0 |
| 973 | Molecular Pathology of Gastric Cancer. Journal of Gastric Cancer, 2022, 22, 264. | 0.9 | 6 |
| 974 | Smart bio-encapsulation for immunotherapy. , 2022, , 75-90. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 975 | Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. Biomaterials Science, 2022, 10, 6755-6767. | 2.6 | 3 |
| 976 | Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. International Journal of Molecular Sciences, 2022, 23, 12641. | 1.8 | 6 |
| 977 | Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. Journal of Immunotherapy, 2023, 46, 43-55. | 1.2 | 4 |
| 978 | CXCL8 Up-Regulated LSECtin through AKT Signal and Correlates with the Immune Microenvironment Modulation in Colon Cancer. Cancers, 2022, 14, 5300. | 1.7 | 4 |
| 979 | Optogenetic-controlled immunotherapeutic designer cells for post-surgical cancer immunotherapy. Nature Communications, 2022, 13, . | 5.8 | 12 |
| 980 | Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy. Frontiers in Genetics, 0, 13, . | 1.1 | 4 |
| 981 | Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |
| 982 | Cancer-associated inflammation: pathophysiology and clinical significance. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2657-2672. | 1.2 | 10 |
| 983 | Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. Cancers, 2022, 14, 4985. | 1.7 | 5 |
| 984 | Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood. Biomedicines, 2022, 10, 2534. | 1.4 | 1 |
| 985 | Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. Frontiers in Pharmacology, 0, 13, . | 1.6 | 3 |
| 986 | Precision Medicine in the Treatment of Locally Advanced or Metastatic Urothelial Cancer: New Molecular Targets and Pharmacological Therapies. Cancers, 2022, 14, 5167. | 1.7 | 5 |
| 987 | MELK is a prognostic biomarker and correlated with immune infiltration in glioma. Frontiers in Neurology, 0, 13, . | 1.1 | 3 |
| 988 | Immunomodulating Hydrogels as Stealth Platform for Drug Delivery Applications. Pharmaceutics, 2022, 14, 2244. | 2.0 | 4 |
| 989 | Immune-Checkpoint-Inhibitor Therapyâ€"Principles and Relevance of Biomarkers for Pathologists and Oncologists. Advances in Anatomic Pathology, 0, Publish Ahead of Print, . | 2.4 | 0 |
| 990 | The influence of machine learning technologies in gut microbiome research and cancer studies - A review. Life Sciences, 2022, 311, 121118. | 2.0 | 5 |
| 991 | Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?. Pharmaceutics, 2022, 14, 2326. | 2.0 | 2 |
| 992 | <scp>MYC</scp> and therapy resistance in cancer: risks and opportunities. Molecular Oncology, 2022, 16, 3828-3854. | 2.1 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 993 | The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges. Applied Sciences (Switzerland), 2022, 12, 10548. | 1.3 | 0 |
| 994 | Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy. Critical Reviews in Oncology/Hematology, 2022, 180, 103863. | 2.0 | 1 |
| 995 | Interplay between the DNA Damage Response and Immunotherapy Response in Cancer. International Journal of Molecular Sciences, 2022, 23, 13356. | 1.8 | 3 |
| 996 | Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022. | 1.1 | 4 |
| 997 | Immunotherapy approaches for hematological cancers. IScience, 2022, 25, 105326. | 1.9 | 9 |
| 998 | The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. Cancer Letters, 2022, 551, 215947. | 3.2 | 1 |
| 999 | Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. Journal of Controlled Release, 2022, 352, 328-337. | 4.8 | 4 |
| 1000 | Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy. Biomaterials, 2022, 291, 121871. | 5.7 | 23 |
| 1001 | The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences, 2022, 310, 121138. | 2.0 | 14 |
| 1002 | TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC. Biochemistry and Biophysics Reports, 2022, 32, 101359. | 0.7 | 1 |
| 1003 | Unraveling the peripheral and local role of inflammatory cytokines in glioblastoma survival. Cytokine, 2023, 161, 156059. | 1.4 | 3 |
| 1004 | The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance. Cytokine, 2023, 161, 156081. | 1.4 | 3 |
| 1005 | The New T Cell Subset Opens a New Realm for Tumor Immunotherapy. Cell Transplantation, 2022, 31, 096368972211380. | 1.2 | 1 |
| 1006 | Immunotherapy as an emerging and promising tool against viral infections. , 2023, , 625-651. | | 0 |
| 1007 | Advances in Targeted Immunotherapy for Hepatobiliary Cancers. International Journal of Molecular Sciences, 2022, 23, 13961. | 1.8 | 10 |
| 1008 | Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 1009 | Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study. Scientific Reports, 2022, 12, . | 1.6 | 7 |
| 1010 | Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences, 2022, 23, 14121. | 1.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1011 | Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. Cancers, 2022, 14, 5618. | 1.7 | 2 |
| 1012 | Emerging evidence of immunotherapy for colorectal cancer. Annals of Gastroenterological Surgery, 2023, 7, 216-224. | 1.2 | 4 |
| 1013 | New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome. Oncogematologiya, 2022, 17, 106-117. | 0.1 | 0 |
| 1014 | Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 4327-4347. | 5.7 | 78 |
| 1015 | Ginseng fermentation solution is associated with immune response in lung adenocarcinoma by modulating the differential expression of the m7G regulators. Journal of Functional Foods, 2022, 99, 105337. | 1.6 | 0 |
| 1016 | Identification of fatty acid metabolismâ€“related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 1017 | Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers. Cancers, 2022, 14, 5663. | 1.7 | 5 |
| 1018 | Folate Receptorâ€Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. Small, 2023, 19, . | 5.2 | 12 |
| 1019 | A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma. Translational Andrology and Urology, 2021, . | 0.6 | 0 |
| 1020 | Intra-Tumor Cell Heterogeneity: Different Immune Responses for Different Cells. , 2022, , 1-26. | | 0 |
| 1021 | Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy. Theranostics, 2023, 13, 40-58. | 4.6 | 6 |
| 1022 | Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology, 2023, 88, 81-95. | 4.3 | 11 |
| 1023 | Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis. Gene, 2023, 856, 147132. | 1.0 | 1 |
| 1024 | Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211340. | 1.4 | 1 |
| 1025 | The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations. Cells, 2022, 11, 3818. | 1.8 | 6 |
| 1026 | Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. Vaccines, 2022, 10, 2049. | 2.1 | 0 |
| 1027 | Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. Journal of Immunotherapy and Precision Oncology, 2022, 5, 98-104. | 0.6 | 7 |
| 1028 | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines, 2022, 10, 1993. | 2.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1029 | Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Frontiers in Genetics, 0, 13, . | 1.1 | 0 |
| 1030 | Analysis of Hepatic Adverse Event in Patients Treated with Immune Checkpoint Inhibitor. Journal of Korean Society of Health-System Pharmacists, 2022, 39, 476-487. | 0.1 | 0 |
| 1031 | KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. Frontiers in Oncology, 0, 12, . | 1.3 | 27 |
| 1033 | Baseline immune signature score of Tregs Ã— HLA-DR+CD4+ T cells Ã— PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 1034 | Adrenal Gland. , 2022, , 189-273. | | 0 |
| 1035 | YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment. Frontiers in Chemistry, 0, 10, . | 1.8 | 1 |
| 1036 | Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment. Scientific Reports, 2022, 12, . | 1.6 | 1 |
| 1037 | A practical approach for PD-L1 evaluation in gastroesophageal cancer. Pathologica, 2023, 115, 57-70. | 1.3 | 2 |
| 1038 | Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. Frontiers in Materials, 0, 9, . | 1.2 | 0 |
| 1039 | The difficulty in translating the preclinical success of combined TGFÎ² and immune checkpoint inhibition to clinical trial. EBioMedicine, 2022, 86, 104380. | 2.7 | 17 |
| 1040 | Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 1041 | Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5497-5512. | 1.2 | 11 |
| 1042 | TGF-Î²: A novel predictor and target for anti-PD-1/PD-L1 therapy. Frontiers in Immunology, 0, 13, . | 2.2 | 22 |
| 1043 | Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41. | 1.8 | 6 |
| 1044 | Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma. Frontiers in Genetics, 0, 13, . | 1.1 | 2 |
| 1045 | Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell International, 2022, 22, . | 1.8 | 3 |
| 1046 | Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Antiâ€“PD-1 and Antiâ€“PD-L1 Treatment in a Checkpoint Refractory Melanoma Model. Cancer Immunology Research, 2023, 11, 217-227. | 1.6 | 4 |
| 1048 | Introduction on Personalized Immune-Oncology. , 2023, , 1-25. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1049 | Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System. Current Pharmaceutical Biotechnology, 2023, 24, 1351-1364. | 0.9 | 3 |
| 1050 | Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events AfterÂImmunotherapy. JACC: CardioOncology, 2022, 4, 660-669. | 1.7 | 7 |
| 1051 | The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Molecular Biosciences, 0, 9, . | 1.6 | 4 |
| 1052 | CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma. World Journal of Surgical Oncology, 2022, 20, . | 0.8 | 1 |
| 1053 | Systemic immuneâ€“inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy, 2022, 14, 1481-1496. | 1.0 | 26 |
| 1054 | Nanovaccines for cancer immunotherapy: Current knowledge and future perspectives. Chinese Chemical Letters, 2023, 34, 108098. | 4.8 | 6 |
| 1055 | Diverse effects of obesity on antitumor immunity and immunotherapy. Trends in Molecular Medicine, 2022, , . | 3.5 | 2 |
| 1056 | Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Cancers, 2022, 14, 6145. | 1.7 | 10 |
| 1057 | Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology, 2023, 102, 151284. | 1.6 | 8 |
| 1058 | Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework. Frontiers in Pharmacology, 0, 13, . | 1.6 | 1 |
| 1059 | Integrative stemness characteristics associated with prognosis and the immune microenvironment in lung adenocarcinoma. BMC Pulmonary Medicine, 2022, 22, . | 0.8 | 1 |
| 1061 | Current Targeted Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2023, 24, 1702. | 1.8 | 22 |
| 1062 | Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. Oncologist, 2023, 28, 440-448. | 1.9 | 8 |
| 1063 | The effect of Wnt/Î²-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. Oncology Research, 2022, 30, 99-116. | 0.6 | 7 |
| 1064 | Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. International Journal of Molecular Sciences, 2023, 24, 1280. | 1.8 | 5 |
| 1065 | Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology, Immunotherapy, 2023, 72, 1365-1379. | 2.0 | 93 |
| 1066 | Identification of cuproptosis related subtypes and construction of prognostic signature in gastric cancer. Frontiers in Surgery, 0, 9, . | 0.6 | 0 |
| 1067 | A circadian rhythm-related gene signature for prognosis, invasion and immune microenvironment of breast cancer. Frontiers in Genetics, 0, 13, . | 1.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1068 | The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 1069 | Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis B or C: A Systematic Review and Meta-Analysis. Journal of Oncology, 2023, 2023, 1-13. | 0.6 | 0 |
| 1070 | Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. Frontiers in Neurology, 0, 13, . | 1.1 | 3 |
| 1071 | Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis. Frontiers in Oncology, 0, 12, . | 1.3 | 1 |
| 1072 | Biomaterialâ€Based In Situ Cancer Vaccines. Advanced Materials, 0, , . | 11.1 | 13 |
| 1073 | The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy. Journal of Immunotherapy and Precision Oncology, 2023, 6, 84-90. | 0.6 | 6 |
| 1074 | Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS ONE, 2023, 18, e0280364. | 1.1 | 2 |
| 1075 | Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP+ fibroblasts in stomach adenocarcinoma. Cancer Immunology, Immunotherapy, 0, , . | 2.0 | 0 |
| 1076 | Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse event. Endocrinology, Diabetes and Metabolism Case Reports, 2023, 2023, . | 0.2 | 1 |
| 1077 | CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. PeerJ, 0, 11, e14668. | 0.9 | 0 |
| 1078 | Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer. Journal of Cancer Policy, 2023, 35, 100382. | 0.6 | 1 |
| 1079 | Modified method for differentiation of myeloid-derived suppressor cells in vitro enhances immunosuppressive ability via glutathione metabolism. Biochemistry and Biophysics Reports, 2023, 33, 101416. | 0.7 | 1 |
| 1080 | Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment. Coordination Chemistry Reviews, 2023, 480, 215027. | 9.5 | 23 |
| 1081 | Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide. Pharmaceutics, 2023, 15, 130. | 2.0 | 1 |
| 1082 | Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines, 2023, 11, 83. | 1.4 | 3 |
| 1083 | Cerebellar High-Grade Glioma: A Translationally Oriented Review of the Literature. Cancers, 2023, 15, 174. | 1.7 | 1 |
| 1084 | Improved cancer immunotherapy strategies by nanomedicine. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2023, 15, . | 3.3 | 7 |
| 1085 | The Rise in Immunotherapy and Associated Ocular Toxicities. , 2022, , 337-347. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1086 | Immune Checkpoint Inhibitors and Optic Neuropathy: A Systematic Review. Seminars in Ophthalmology, 2023, 38, 547-558. | 0.8 | 1 |
| 1087 | Infection and Immunity. , 2023, , 493-598. | | 1 |
| 1088 | Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. Scientific Reports, 2023, 13, . | 1.6 | 2 |
| 1089 | Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study. Journal of Personalized Medicine, 2023, 13, 206. | 1.1 | 0 |
| 1090 | Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma. BioMed Research International, 2023, 2023, 1-22. | 0.9 | 0 |
| 1091 | Comprehensive Analysis of KCNJ14 Potassium Channel as a Biomarker for Cancer Progression and Development. International Journal of Molecular Sciences, 2023, 24, 2049. | 1.8 | 3 |
| 1092 | Perspective Chapter: Impact of Tumor Metabolism on Immune Cells in the Tumor Microenvironment. , 0, , . | | 0 |
| 1093 | Immunotherapy for Breast Cancer. , 2023, , 1-30. | | 0 |
| 1094 | Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. Journal of Immunology Research, 2023, 2023, 1-17. | 0.9 | 3 |
| 1095 | Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Current Opinion in Oncology, 2023, 35, 94-99. | 1.1 | 4 |
| 1096 | Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. Life Sciences, 2023, 318, 121459. | 2.0 | 6 |
| 1097 | High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle. Disease Markers, 2023, 2023, 1-20. | 0.6 | 4 |
| 1098 | Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immuneâ€Suppressive Cells with a Nanoparticulated Antiâ€Inflammatory Drug. Small, 2023, 19, . | 5.2 | 1 |
| 1099 | An Overview of Polymeric Nanoparticles-Based Drug Delivery System in Cancer Treatment. Technology in Cancer Research and Treatment, 2023, 22, 153303382311520. | 0.8 | 17 |
| 1100 | Immunotherapies in rare cancers. Molecular Cancer, 2023, 22, . | 7.9 | 15 |
| 1101 | Research Advances in Immunotherapy for Pancreatic Cancer. Advances in Clinical Medicine, 2023, 13, 3457-3462. | 0.0 | 0 |
| 1102 | Current Treatment Approaches to Breast Cancer. , 2023, , 23-51. | | 0 |
| 1103 | The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas. Cells, 2023, 12, 755. | 1.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1104 | Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses. Frontiers in Pharmacology, 0, 14, . | 1.6 | 3 |
| 1105 | Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. Frontiers in Genetics, 0, 14, . | 1.1 | 2 |
| 1106 | T Cell-Association of Carboxy-Terminal Dendrimers with Different Bound Numbers of Phenylalanine and Their Application to Drug Delivery. Pharmaceutics, 2023, 15, 888. | 2.0 | 2 |
| 1107 | PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. Journal of Biomedical Science, 2023, 30, . | 2.6 | 4 |
| 1108 | Application of radiomics in lung immunoâ€oncology. Precision Radiation Oncology, 2023, 7, 128-136. | 0.4 | 1 |
| 1109 | ER stress modulates the immune regulatory ability in gut M2 cells of patients with ulcerative colitis. IScience, 2023, 26, 106498. | 1.9 | 0 |
| 1110 | Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882. | 1.7 | 2 |
| 1111 | Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. International Immunopharmacology, 2023, 117, 109881. | 1.7 | 8 |
| 1112 | In vitro models of breast cancer bone metastasis: analyzing drug resistance through the lens of the microenvironment. Frontiers in Oncology, 0, 13, . | 1.3 | 1 |
| 1113 | Brazilein inhibits epithelial-mesenchymal transition (EMT) and programmed death ligand 1 (PD-L1) expression in breast cancer cells. International Immunopharmacology, 2023, 118, 109988. | 1.7 | 1 |
| 1114 | Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities. Biomedicine and Pharmacotherapy, 2023, 162, 114601. | 2.5 | 2 |
| 1115 | Mechano-modulation of T cells for cancer immunotherapy. Biomaterials, 2023, 297, 122101. | 5.7 | 5 |
| 1116 | Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. Computers in Biology and Medicine, 2023, 159, 106866. | 3.9 | 0 |
| 1118 | Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data. Oncologie, 2022, 24, 835-863. | 0.2 | 5 |
| 1119 | A Novel Triâ€Functional Liposome Reâ€Educates â€œCold Tumorâ€•and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PDâ€L1 Blockade. Advanced Healthcare Materials, 2023, 12, . | 3.9 | 3 |
| 1120 | Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer. Frontiers in Oncology, 0, 13, . | 1.3 | 3 |
| 1121 | Macrophage Repolarization as a Therapeutic Strategy for Osteosarcoma. International Journal of Molecular Sciences, 2023, 24, 2858. | 1.8 | 9 |
| 1122 | A Rare Case of Pembrolizumab-Associated Gravesâ€™ Disease. Cureus, 2023, , . | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1124 | Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer, 2023, 23, . | 1.1 | 4 |
| 1125 | Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics. Cell Death Discovery, 2023, 9, . | 2.0 | 6 |
| 1126 | The Genesâ€“Stemnessâ€“Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints. International Journal of Molecular Sciences, 2023, 24, 3496. | 1.8 | 0 |
| 1127 | Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. Immuno-Oncology Technology, 2023, 17, 100374. | 0.2 | 4 |
| 1128 | Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6513-6526. | 1.2 | 1 |
| 1129 | Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines, 2023, 11, 528. | 1.4 | 0 |
| 1130 | <italic>Salmonella typhimurium</italic> may support cancer treatment: a review. Acta Biochimica Et Biophysica Sinica, 2023, 55, 331-342. | 0.9 | 2 |
| 1131 | Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1132 | Lessons learned from evolving frameworks in adult glioblastoma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 131-140. | 1.0 | 1 |
| 1133 | OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic TÂcell differentiation spectrum. Cell Reports Medicine, 2023, 4, 100939. | 3.3 | 6 |
| 1134 | CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer. Cancers, 2023, 15, 1262. | 1.7 | 7 |
| 1135 | Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells. Journal of Cancer Research and Clinical Oncology, 2023, 149, 6583-6599. | 1.2 | 2 |
| 1136 | Hypercholesterolemia Influences the Progression of Cancer by Changing the Biomolecular and Immunological Status of the Tumor Microenvironment. , 2023, , 1-30. | | 0 |
| 1137 | X-ray irradiation negatively affects immune responses in the lymphatic network. Microvascular Research, 2023, 148, 104511. | 1.1 | 1 |
| 1138 | COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review. Journal of Immunotherapy and Precision Oncology, 2023, 6, 103-110. | 0.6 | 0 |
| 1139 | The temporal behavior of the murine T cell receptor repertoire following Immunotherapy. Scientific Data, 2023, 10, . | 2.4 | 0 |
| 1140 | Elevated NDC1 expression predicts poor prognosis and correlates with immunity in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2023, 14, 245-264. | 0.6 | 2 |
| 1141 | Novel biomaterials for stem cell engineering and bone regeneration. , 2023, , 169-204. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1142 | Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives. Journal of Controlled Release, 2023, 356, 14-25. | 4.8 | 7 |
| 1143 | The Effect of Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study. Clinical Oncology, 2023, , . | 0.6 | 3 |
| 1144 | Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: A systemic review and meta-analysis. Open Life Sciences, 2023, 18, . | 0.6 | 1 |
| 1145 | Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database. Annals of Translational Medicine, 2023, 11, 163-163. | 0.7 | 0 |
| 1146 | Î²3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-Î³-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. Cancer Gene Therapy, 2023, 30, 890-904. | 2.2 | 5 |
| 1147 | CD39/CD73/A2AR pathway and cancer immunotherapy. Molecular Cancer, 2023, 22, . | 7.9 | 43 |
| 1148 | The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, . | | 0 |
| 1149 | Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis. Current Oncology, 2023, 30, 2997-3019. | 0.9 | 3 |
| 1150 | Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis. Frontiers in Oncology, 0, 13, . | 1.3 | 3 |
| 1151 | A Bispecific Peptideâ€Polymer Conjugate Bridging Targetâ€Effector Cells to Enhance Immunotherapy. Advanced Healthcare Materials, 2023, 12, . | 3.9 | 0 |
| 1152 | Photon-Controlled Pyroptosis Activation (PhotoPyro): An Emerging Trigger for Antitumor Immune Response. Journal of the American Chemical Society, 2023, 145, 6007-6023. | 6.6 | 35 |
| 1153 | Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 1154 | The construction of a novel ferroptosis-related lncRNA model to predict prognosis in colorectal cancer patients. Medicine (United States), 2023, 102, e33114. | 0.4 | 0 |
| 1155 | Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis. Frontiers in Immunology, 0, 14, . | 2.2 | 2 |
| 1156 | Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression. Journal of Clinical Investigation, 2023, 133, . | 3.9 | 10 |
| 1157 | Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis. Clinical and Experimental Medicine, 2023, 23, 2041-2050. | 1.9 | 1 |
| 1158 | Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint. Scientific Reports, 2023, 13, . | 1.6 | 6 |
| 1159 | Application and Prospect between m6A and LncRNA in Pancreatic Cancer. Advances in Clinical Medicine, 2023, 13, 3883-3888. | 0.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1160 | Applications of immune checkpoint inhibitors (ICIs) in the medical fields. , 0, 36, 321-330. | | 0 |
| 1161 | CAR-T cells therapy: a potential new strategy against prostate cancer. , 0, 36, 1468-1473. | | 0 |
| 1162 | Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma. Journal of Translational Medicine, 2023, 21, . | 1.8 | 7 |
| 1163 | Terminally Exhausted CD8+ T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells. Cancer Research, 2023, 83, 1815-1833. | 0.4 | 7 |
| 1164 | Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. Discover Oncology, 2023, 14, . | 0.8 | 2 |
| 1165 | Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. Frontiers in Oncology, 0, 13, . | 1.3 | 2 |
| 1166 | Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report. BMC Neurology, 2023, 23, . | 0.8 | 1 |
| 1167 | Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis. BMC Cancer, 2023, 23, . | 1.1 | 3 |
| 1168 | Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPÎ± Checkpoint Blockade for Efficient Treatment of Colon Cancer. Molecules, 2023, 28, 3147. | 1.7 | 6 |
| 1169 | Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma. Frontiers in Immunology, 0, 14, . | 2.2 | 0 |
| 1170 | Anti-cancer therapeutic agents and carpal tunnel syndrome: Clinical, electrodiagnostic, and ultrasound findings in seven patients. Journal of Oncology Pharmacy Practice, 2024, 30, 38-45. | 0.5 | 0 |
| 1171 | Novel Systemic Approaches for the Management of Meningiomas. Neurosurgery Clinics of North America, 2023, , . | 0.8 | 1 |
| 1172 | Epidemiology of Melanoma. , 0, , . | | 0 |
| 1173 | PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics, 2023, 13, 1876-1891. | 4.6 | 2 |
| 1175 | A cuproptosis-related lncRNA signature to predict prognosis and immune microenvironment of colon adenocarcinoma. Scientific Reports, 2023, 13, . | 1.6 | 0 |
| 1176 | Ectopic expression of cGAS inSalmonella typhimuriumenhances STING-mediated IFN-Î² response in human macrophages and dendritic cells. , 2023, 11, e005839. | | 1 |
| 1177 | TFAP2A promotes cervical cancer via aÂpositive feedback pathway with PDâ€'L1. Oncology Reports, 2023, 49, . | 1.2 | 1 |
| 1178 | Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2621-2635. | 3.3 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1219 | Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. British Journal of Cancer, 2023, 129, 24-37. | 2.9 | 7 |
| 1227 | The Dawn of a New Era: Targeting the â€œUndruggablesâ€•with Antibody-Based Therapeutics. Chemical Reviews, 2023, 123, 7782-7853. | 23.0 | 13 |
| 1229 | An Fc Binding Peptide-Based Facile and Versatile Build Platform for Multispecific Antibodies. Nano Letters, 2023, 23, 4191-4200. | 4.5 | 4 |
| 1235 | Functional roles of sphingolipids in immunity and their implication in disease. Experimental and Molecular Medicine, 2023, 55, 1110-1130. | 3.2 | 9 |
| 1262 | Metal-based drug delivery systems for cancer immunotherapy. , 2023, , 851-891. | | 0 |
| 1288 | Case report: Identification of potential prognosis-related LAG3 overexpression and DICER1 mutation in pituitary carcinoma: two cases. Frontiers in Neuroscience, 0, 17, . | 1.4 | 0 |
| 1293 | Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 17663-17670. | 1.2 | 0 |
| 1296 | Systemic Onco-Sphere: Host Neuronal System in Cancer. , 2023, , 511-534. | | 0 |
| 1301 | Targeting immune checkpoints for cancer therapy. , 2023, , 95-134. | | 0 |
| 1326 | PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 2023, 72, 3875-3893. | 2.0 | 4 |
| 1327 | Development of pauci-immune necrotizing glomerulonephritis during pembrolizumab treatment. Clinical and Experimental Nephrology, 0, , . | 0.7 | 0 |
| 1356 | Hepatocellular Carcinoma and Human Gut Microbiome: Association with Disease and Scope for Therapeutic Intervention. , 2023, , 127-149. | | 0 |
| 1359 | Recent Advances in RNA m6A Modification in Solid Tumors and Tumor Immunity. Cancer Treatment and Research, 2023, , 95-142. | 0.2 | 0 |
| 1374 | Recent advances in light-triggered cancer immunotherapy. Journal of Materials Chemistry B, 2024, 12, 2650-2669. | 2.9 | 0 |
| 1385 | Translational bioinformatics approach to combat cardiovascular disease and cancers. Advances in Protein Chemistry and Structural Biology, 2024, , 221-261. | 1.0 | 1 |
| 1406 | LAG-3 Inhibitors for the Treatment of Lung Cancer. , 2024, , 131-152. | | 0 |